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Angiogenesis in parathyroid disease and association with VEGF
Angiogenesis has been demonstrated in normal parathyroid tissue in vitro and must occur in vivo to
allow for successful transplantation. Here we present data that angiogenesis also occurs in parathyroid
disease states and that VEGF (a known endothelial cell mitogen) expression is not evident in these
tissues.
Formalin fixed, paraffin embedded sections of human parathyroid tissue were stained with an
antibody to CD31 to visualise endothelial cells and separate sections stained with antibody to VEGF
using standard immunohistochemistry techniques. Microvessel counts were performed by two
(blinded) investigators. Western blot analysis ofprotein lysate of parathyroid tissue was also
performed using antibody to VEGF.
123 patients were studied (44 normal, 27 hyperplasia and 52 adenoma). Microvessel counts showed a
statistically significant (p < 0.05 compared with normal) and step-wise increase in microvessel count
between the different types of tissue. 120 parathyroid sections stained with antibody to VEGF with
positive control of normal kidney showed non-specific staining in all tissue types, a finding which was
repeated with Western blot analysis of protein derived from 1 normal, 2 adenomas and 2 hyperplasia
samples.
Here we have demonstrated evidence of angiogenesis that occurs in human parathyroid tissue when
diseased. Our data have not shown a significant expression ofVEGF in these samples. This finding
implies that either VEGF does not mediate angiogenesis in these tissues or that it does so transiently.
Alternatively VEGF may act in concentrations too small to be detected with these techniques. Gaining
a better understanding of the progression of angiogenesis in parathyroid disease may lead to the
development of novel therapeutic strategies.
Changes in Vascularity Associated with Chronic Allograft Nephropathy
This study aims to compare vascularity of kidneys with CAN versus normal. In addition, validation of
renal biopsy samples in the assessment of angiogenesis has been performed.
Tissue from transplant nephrectomies performed because ofCAN (n=29), antecedent biopsies from
these grafts (n=18) and normal kidneys (n=61) were studied. Protocol renal transplant biopsies were
also studied. Tissue sections were immunostained with the endothelial cell antibody to CD31.
Changes in overall vascular patterns were noted and microvessel counts performed. Sections were
dual-stained with antibody to CD31 and the proliferation marker, MIB-1, to determine the presence of
proliferating endothelial cells. Microvessel counts were performed on paired samples of core biopsies
and cross-section of normal kidney and were compared in early protocol biopsy specimens from grafts
which develop CAN (n=10) with those where stable graft function continued (n=20). Macrophage
infiltration was studied using immunostaining to CD68.
CD31 staining from CAN nephrectomies exhibited diminished cortical and medullary staining and
was accompanied by a significant increase in proliferation index when compared with normal. There
was significant correlation in microvessel counts in core biopsies and the corresponding kidney cross-
section. Early biopsies from grafts which developed CAN show significantly higher microvessel
counts compared with the corresponding nephrectomy. The number of proliferating ECs was
significantly increased in this biopsy group compared with normal kidney but was not significantly
different compared with the CAN nephrectomy group. Early protocol biopsies from grafts which
developed CAN showed significantly higher microvessel counts compared with those with stable graft
function. A significant increase in macrophage infiltration was seen in CAN nephrectomies compared
with normal kidney.
This study demonstrates reduced density ofCD31-positive microvessels in CAN compared with
normal. In addition, the investigation of changes in the microvasculature in CAN by study of core
biopsies has been validated and confirms preservation ofnormal vasculature in early CAN. Together
with evidence of proliferating endothelial cells these findings support a hypothesis that, early in the
development ofCAN, angiogenesis is stimulated, but despite this attempt at tissue repair, progressive
microvascular loss occurs. The presence of significant numbers ofmacrophages may be of
aetiological importance or reflect changes relating to cessation of immunosuppression.
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Chapter 1; Introduction
This thesis examines changes in vascularity in two diseases affecting patients with
end stage renal failure: parathyroid disease and chronic allograft nephropathy. In
clinical practice, chronic renal failure (CRT) links these two conditions. CRF is
associated with secondary hyperparathyroidism due to failure of kidneys to
metabolise vitamin D effectively. One therapeutic option for end stage renal failure is
transplantation and a common cause of loss of kidney transplants after one year is
chronic allograft nephropathy (CAN).
The work undertaken in this study will present data for each condition separately.




Parathyroid glands in mammals play a central role in the regulation of calcium
homeostasis through secretion ofparathyroid hormone. This 84 amino acid peptide
has a half life of a few minutes and acts on cell membrane receptors to increase
cellular cAMP. It acts on bone, kidney and gut (Cohn et al 1986).
Table 1.1: End organ effects ofPTH
Tissue Action
Bone Increases turnover of bone and stimulates
calcium release
Kidney Increases production of 1,25 dihydroxy-
vitamin D3
Gut Increases calcium absorption from small
intestine
Secretion ofparathyroid hormone increases in response to low levels of serum
calcium such that calcium resorption from bone occurs, renal losses of calcium
reduce and absorption from the gut increases until normal levels of calcium are
restored (Cohn et al 1986, Brown et al 1995, Slatopolsky et al 1999). In the majority
of the human population there are four parathyroid glands situated in the neck,
although ~4% ofpeople will have more than four glands and up to 25% of patients
may have supernumerary and/or aberrant glands.
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The differential diagnoses in hypercalcaemia are:
• primary hyperparathyroidism
• renal failure and secondary or tertiary hyperparathyroidism
• malignancy
• granulomatous disease e.g. sarcoid, TB
• drugs e.g. thiazide diurectics, vitamin D toxicity, lithium





Hyperparathyroidism is a condition in which increased levels ofparathyroid
hormone are found in the blood. Three main types are recognized: primary,
secondary and tertiary. In the primary form increased parathyroid hormone secretion
occurs as a result of abnormality in one or more of the parathyroid glands, usually
owing to the presence of adenoma or rarely carcinoma. In this form the fundamental
biochemical finding is persistent hypercalcaemia. The secondary form is associated
with abnormalities of parathyroid function induced by a sustained hypocalcaemic
stimulus, often resulting from chronic renal failure or malabsorption states. In
secondary hyperparathyroidism, renal abnormality is associated with additional soft
tissue and skeletal changes, and the entire complex is termed renal osteodystrophy
(Akizawa et al 1999, Beckerman et al 1999). Tertiary hyperparathyroidism is found
in patients with chronic renal failure or malabsorption and secondary
hyperparathyroidism of long duration who develop relatively autonomous
parathyroid function and hypercalcaemia (Fukagawa 1999). This situation also
occurs following renal transplantation when the stimulus to PTH secretion has been
removed but parathyroid glands function autonomously. The clinical features of
primary and secondary hyperparathyroidism differ in some respects (Table 1.2).
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Brown tumours Common Less common
Osteosclerosis Rare Common
Chondrocalcinosis Not infrequent Rare
Periostitis Rare Not infrequent
Hyperparathyroidism leads to considerable bone erosion involving subperiosteal,
intracortical, endosteal, trabecular, subchondral and subligamentous foci. In renal
osteodystrophy, additional features are noted, including osteomalacia, osteoporosis,
and soft tissue and vascular calcification. Haemodialysis and renal transplantation
may cause these findings to become exaggerated or arrested.
Bone tissue in hyperparathyroidism demonstrates osteitis fibrosa cystica, with
replacement ofmarrow elements by highly vascular fibrous tissue, as well as
osteoporosis and osteomalacia. Localized cysts or brown tumours may also be seen.
Bone resorption in the hands can be identified in the early stages of the disease by
high quality radiography. Subperiosteal resorption of cortical bone is virtually
diagnostic of hyperparathyroid bone disease. Brown tumours, representing localized
accumulations of fibrous tissue and giant cells, can replace bone and even may
produce osseous expansion.
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Brown tumours appear as single or multiple well-defined lesions of the axial or
appendicular skeleton. Common sites of involvement are the facial bones, pelvis, ribs
and femora.
Bone sclerosis, marked by diffuse increase in bone density, may be apparent in the
metaphyseal regions of the long bones, the skull or the vertebral endplates. In
addition, deposition of bone in the subchondral areas of the vertebral bodies leads to
the appearance of radiodense bands across the superior and inferior margins (rugger
jersey spine).
Primary hyperparathyroidism is frequently associated with chondrocalcinosis. Other
rheumatologic manifestations include capsular and ligamentous laxity, as well as
rupture, contributing to joint instability, traumatic synovitis, and cartilaginous and
osseous destruction. Monosodium urate crystal deposition and clinical gout have also
been described in patients with hyperparathyroidism.
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Treatment of Parathyroid Disease
Primary hyperparathyroidism is diagnosed when a patient presents with an elevated
serum calcium level in conjunction with elevated levels of parathyroid hormone. In
these cases an adenoma of one of the parathyroid glands is seen although
occasionally more than one gland may be affected. In the patient fit to undergo
surgery the treatment of choice is excision of the affected gland. Because three
glands are left in the patient calcium homeostasis is restored in the majority of cases.
Secondary hyperparathyroidism occurs when there is appropriate increase in the
secretion of parathyroid hormone in response to a persistently low level of serum
calcium as can occur in chronic renal failure where it is related to the inability of
failing kidneys to convert vitamin D to its active form. All four parathyroid glands
are affected with histological features ofhyperplasia. Overt osteodystrophy will
develop in 10% to 25% ofpatients receiving long-term dialysis treatment (Mozes et
al 1980). Treatment in this instance will sometimes require excision of the affected
parathyroid tissue and this can be done using one of three methods:
- total parathyroidectomy with lifelong calcium and/or vitamin D supplementaion,
- total parathyroidectomy with autotransplantation of a small amount ofparathyroid
tissue into forearm muscle (Wells et al 1975)
- subtotal parathyroidectomy where the majority of parathyroid tissue is excised but a
portion of one vascular gland is left within the neck.
In each instance the aim of treatment is restoration of normal calcium homeostasis
and parathyroid function with the hope that further surgery will not be required to
treat recurrent disease. Each method has advantages and disadvantages. With total
parathyroidectomy and autotransplantation over 90% of grafts function successfully
(Takagi et al 1983) and with appropriate PTH release in response to changes in
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serum calcium concentrations (Schneider et al 1977, Brown et al 1979) but in those
that do not there is no remaining functioning parathyroid tissue with the patient
requiring lifelong calcium supplementation. This method avoids the need for a
second and more difficult neck dissection close to vital structures, such as the
recurrent laryngeal nerve, should disease recur. Excision ofparathyroid implants
from forearm muscle is safer and can often be performed under local anaesthesia. In
the long term the majority of these implants will require excision due to disease
recurrence. By performing a subtotal parathyroidectomy the uncertainty over graft
function is removed and restoration of calcium homeostasis is achieved. However
there is a risk that insufficient functioning parathyroid tissue remains either due to
excision of too much of the gland or vascular compromise to the remaining gland.
Should disease recur, further challenging neck surgery is required with associated
morbidity in some cases.
Further research is required to identify the precise mechanisms by which parathyroid
glands become diseased. Surgical debate will continue as to which operative method
is of greatest benefit and central to this discussion are the criteria used for evaluating
success (Saxe 1984). Medical control of secondary hyperparathyroidism, obviating
the need for surgery, may be a realistic therapeutic target for most patients but
current therapies do not yet achieve this (Goodman 2004a).
Current therapeutic strategies rely largely on the use ofvitamin D sterols to diminish
excess PTH synthesis and to lower serum or plasma PTH levels. However their use is
often confounded by increases in serum calcium or phosphate concentrations which
can aggravate soft tissue and vascular calcification (Goodman 2004a). Thus the
development ofnew, more physiologically relevant therapies which may lead to the
successful management of these conditions is needed (Moe et al 2003). One area of
interest is the control ofneovascularisation in the diseased gland
The process of angiogenesis is the focus of interest in this thesis.
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Angiogenesis
In this section, the process of angiogenesis is outlined and mechanisms by which it is
mediated considered.
Specific reference to angiogenesis in parathyroid disease is made in the discussion of
chapter 3 and a detailed review of a known inducer of angiogenesis, vascular
endothelial growth factor, is presented.
The role of angiogenesis during the development of chronic allograft nephropathy is




Angiogenesis is an important physiological process that first occurs in the developing
embryo where the cardiovascular system is the first organ system to develop and
reach functional maturity. It is defined as the growth of new blood vessels from the
endothelium of existing vessels. The term vasculogenesis defines the process ofnew
blood vessel growth from endothelial cell precursors. Both are evident during
embryonic development, but in the normal adult male angiogenesis is quiescent.
'Physiological' angiogenesis occurs in the adult during the process ofwound healing
and as part of the female reproductive cycle (ovulation, menstruation and placental
development) where new blood vessel growth is essential (Wulff et al 2000).
'Pathological' angiogenesis has been implicated in a number ofproliferative
disorders including benign conditions such as retinopathies (Gole et al 1990),
rheumatoid arthritis, Crohn's disease, psoriasis (Colville-Nash et al 1992) as well as
in malignancy.
Angiogenesis is a multistep process involving alterations in endothelial cells and
extracellular matrix remodelling. Figure 1 shows a representation of the steps
involved during tumour induced angiogenesis.
There is local degradation of basement membrane caused by the release of proteases
in the extracellular matrix and endothelial cells around the site of disruption change
shape and invade stroma. These endothelial cells are stimulated to proliferate at the
leading edge of the migrating column, adhering to each other tightly to form tubes
which coalesce to form loops. At this point blood starts to circulate in newly formed
vessels. Endothelial cell proliferation therefore forms an important part of the
process of angiogenesis and investigation of the presence ofproliferating endothelial
cells plays an important part in the studies presented here.
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The majority of published research to date involves the study of angiogenesis during
tumour development as this provides an exciting, potential novel therapeutic target in
the treatment of cancer. Angiogenesis has been shown to be central to both the
growth and metastasis of solid tumours. This complex angiogenic process involves
multiple paracrine and autocrine interactions of stromal and tumour components
(Casey et al 1995, Weidner et al 1992) and the mechanisms of control involve both
stimulatory and inhibitory factors (Hanahan et al 1996). During tumour development,
new vessel formation occurs as an early event and is a discrete component of the
tumour phenotype rather than resulting from tumour hypoxia as the growing mass
outgrows its blood supply (Hanahan et al 1996).
Post-mortem examination of individuals who died of trauma revealed high numbers
of in situ carcinoma. The most striking finding was that virtually all individuals aged
50 to 70 had in situ carcinomas in their thyroid glands despite the fact that only 0.1%
of this age group are diagnosed with thyroid cancer during this period of their life
(Folkman 2004). The suggestion is that many of us carry in situ tumours but that
these are mostly dormant and need additional signals to grow and become potentially
life-threatening cancers. The two-phase theory is thus:
Phase 1: Acquisition ofmutations leads to transformation of normal cells into
cancer cells.
Phase 2: This involves a switch to the angiogenic phenotype, due to constant
recruitment of new blood vessels, which converts non-lethal in situ tumours into an
expanding mass of tumour cells.
It is anticipated that advances made in the field of angiogenesis in tumour biology,
specifically anti-angiogenic strategies that result in the regression of blood vessels
accompanied by tumour cell apoptosis, will be applicable to other settings where
modulation of this process will confer benefit to the patient.
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Regulation of angiogenesis
Recent evidence indicates that new vessel growth and maturation are highly complex
and coordinated processes requiring the sequential activation of a series of receptors
by numerous ligands. Angiogenesis requires activation of quiescent endothelial cells
by growth factors, degradation of the basement membrane and dissociation from the
supporting vascular smooth muscle. These cells must proliferate, survive, migrate
and then differentiate into lumen-bearing structures that may also be lined with
vascular smooth muscle cells. Inhibitors of angiogenesis may block or alter any of
these discrete processes and it is the development of therapeutic agents that act in
this way that provides the focus of clinical trials with anti-angiogenic agents.
Vascular endothelial cell growth factor (VEGF) signalling often represents a crucial
rate-limiting step in physiological angiogenesis and is important in pathological
angiogenesis such as that which occurs during tumour progression. Development of
anti-VEGF monoclonal antibodies that have been used in phase 2 clinical trials have
provided evidence of clinical efficacy in the treatment ofhuman tumours (Ferrara
2002, Ferrara 2004b).
An angiogenic response has been demonstrated by tissue derived from human
parathyroid samples with a histological diagnosis of hyperplasia and adenoma. Using
an in vitro model of angiogenesis, normal canine and human parathyroid tissue have
been shown to stimulate new vessel growth in vitro. Results from the same model of
angiogenesis have shown that, following explant, there is a twelve fold increase in
the expression of vascular endothelial growth factor (VEGF) mRNA as shown by
quantitative reverse transcription polymerase chain reaction (rtPCR) analysis in
human parathyroid cells and furthermore that the angiogenesis stimulated by this
tissue is completely obliterated by coculture with FLT-1 soluble fusion protein
(Carter et al 2000). This work strongly implicates VEGF as being an important
mediator ofparathyroid-induced angiogenesis in this model and it has further been
shown that angiopoietin-2 modulates this response (Carter et al 2001).
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Vascular endothelial growth factor (VEGF)
One of the most important endothelial growth and survival factors is vascular
endothelial growth factor (VEGF) (Ferrara 1999, Ferrara 2004a, Ferrara 2005).
VEGF induces angiogenesis and endothelial cell proliferation and plays an
important role in regulating vasculogenesis. VEGF is a heparin-binding glycoprotein
that is secreted as a homodimer of 45 kDa (Houck et al 1992). Most types of cells,
but usually not endothelial cells themselves, secrete VEGF. VEGF-A increases
vascular permeability and it was known as vascular permeability factor (Dvorak et al.
1999). In addition, VEGF causes vasodilatation, partly through stimulation ofnitric
oxide synthase in endothelial cells (Yang et al 1996) and can also stimulate cell
migration and inhibit apoptosis (Alon et al (1995).
There are several splice variants of VEGF-A. The major ones include: 121, 165, 189
and 206 amino acids (aa), each one comprising a specific exon addition. VEGF165 is
the most predominant protein, but transcripts ofVEGF 121 may be more abundant
(Relf et al 1997). The 165, 189 and 206 aa splice variants have heparin-binding
domains, which help anchor them in extracellular matrix and are involved in binding
to heparin sulfate and presentation to VEGF receptors. This is a key factor for VEGF
potency {i.e., the heparin-binding forms are more active). Several other members of
the VEGF family have been cloned including VEGF-B, -C, and -D (Eriksson et al
1999, Carmeliet et al 1999). Placenta growth factor (P1GF) is also closely related to
VEGF-A. VEGF-A, -B, -C, -D, and P1GF are all distantly related to platelet-derived
growth factors-A and -B. Less is known about the function and regulation ofVEGF-
B, -C, and -D, but they do not seem to be regulated by the major pathways that
regulate VEGF-A.
VEGF-A transcription is potentiated in response to hypoxia and by activated
oncogenes. The transcription factors, hypoxia inducible factor-la (HIF-la) and -2a,
are degraded by proteosomes in normoxia and stabilized in hypoxia (Wegner et al
1997, Kallio et al 1999). This pathway is dependent on the Von Hippel-Lindau gene
product (Maxwell et al 1999). HIF-a and HIF-2 a heterodimerize with the aryl
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hydrocarbon nuclear translocator in the nucleus and bind the VEGF
promoter/enhancer. This is a key pathway expressed in most types of cells. Hypoxia
inducibility, in particular, characterizes VEGF-A compared with other members of
the VEGF family and other angiogenic factors. VEGF transcription in normoxia is
activated by many oncogenes and these pathways together account for a marked
upregulation ofVEGF-A in tumours compared to normal tissues and are often of
prognostic importance (Gaspirini 1997).
There are three receptors in the VEGF receptor family (Shibuya et al 1999,
Kaipainen et al 1997). They have the common properties ofmultiple IgG-like
extracellular domains and tyrosine kinase activity. The enzyme domains ofVEGF
receptor 1 (VEGF Rl, also known as Flt-1), VEGF R2 (also known as KDR or Flk-
1), and VEGF R3 (also known as Flt-4) are divided by an inserted sequence.
Endothelial cells also express additional VEGF receptors, Neuropilin-1 and
Neuropilin-2. VEGF-A binds to Flt-1, KDR and to Neuropilin-1 and Neuropilin-2.
P1GF and VEGF-B bind Flt-1 and Neuropilin-1, VEGF-C and -D bind Flt-4 and
KDR (Neufeld et al 1999, Makinen et al 1999, Migdal et al 1998).
The VEGF-C/Flt-4 pathway is important for lymphatic proliferation (Jeltsch et al
1997). Flt-4 is specifically expressed on lymphatic endothelium. A soluble form of
Flt-1 can be detected in peripheral blood and is a high affinity ligand for VEGF
(Aiello et al 1995). Soluble Flt-1 can be used to antagonize VEGF function. Flt-1 and
KDR are upregulated on tumour and proliferating endothelium, partly by hypoxia
and also in response to VEGF-A itself. Flt-1 is of higher affinity than KDR and
mediates motility and vascular permeability. KDR is necessary for proliferation.
VEGF can be detected in both plasma and serum samples of patients, with much
higher levels in serum (Banks et al 1998). Platelets release VEGF upon aggregation
and may be a major source ofVEGF delivery to tumours (Pinedo et al 1998). Several
studies have shown that the association of high serum levels ofVEGF with poor
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prognosis in cancer patients may be correlated with an elevated platelet count
(O'Byrne et al 1999). Many tumours release cytokines that can stimulate the
production ofmegakaryocytes in the marrow and elevate the platelet count. This can
result in an indirect increase ofVEGF delivery to tumours (Salgado et al 1999).
VEGF is implicated in several other pathological conditions associated with
enhanced angiogenesis. For example, VEGF plays a role in both psoriasis and
rheumatoid arthritis (Koch et al 1994). Diabetic retinopathy is associated with high
intraocular levels ofVEGF. Inhibition ofVEGF function may result in infertility by
blockade of corpus luteum function (Ferrara et al 1998). Interference with VEGF
function has therefore become ofmajor interest in the development of drugs to block
angiogenesis. Approaches include antagonists ofVEGF or its receptors, selective
tyrosine kinase inhibitors, targeting of drugs and toxins to VEGF receptors, and gene
therapy regulated by the same hypoxia pathway that controls VEGF production.




There is intense research to develop new anti-cancer drugs which target
angiogenesis. Such agents can target either tumour derived pro-angiogenic factors
such as VEGF or boost our natural anti-angiogenic defences with the aim to achieve
a balance that prevents further blood vessel growth or causes regression of blood
supply.
Anti-angiogenic strategies might be expected to increase tumour hypoxia and thus
decrease the efficacy of chemotherapy or radiotherapy. It has been shown however
that anti-angiogenic therapy actually increases the efficacy of these conventional
therapies (Hess et al 2001). VEGF has been shown to have direct effects on at least
some tumour cells, acting as a survival factor and protecting them from apoptosis-
inducing therapies (Harmey et al 2002). VEGF is also induced by many
chemotherapy/radiotherapy regimens and may contribute to tumour resistance. By
reversing the increase in vascular permeability induced by VEGF, interstitial fluid
pressure decreases and partial pressure of oxygen increases rendering the tumour
susceptible to other therapies.
Anti-VEGF monoclonal antibody therapies have demonstrated significant blockade
of tumour angiogenesis in rhabdomyosarcoma (Ferrara 2002) and adenovirus
mediated soluble flt-1 VEGF receptor has significantly suppressed tumour growth
and microvessel density in human pancreatic cells (Hoshida et al 2001).
Clinical trials of angiogenesis inhibitors to treat cancer require different guidelines
for their optimum use in animal models and humans (Folkman 2003). A double-blind
placebo controlled phase II has shown a significant increase in time to tumour
progression in renal cell carcinoma patients that were treated with an anti-VEGF
humanized monoclonal antibody (Feldman et al 2002). Such beneficial effects are
not without side effect. TNP-470 is an angiogenesis inhibitor which has been shown
to slow tumour growth in patients with metastatic cancer in clinical trials. However,
at higher doses necessary for tumour regression, many patients experienced
neurotoxicity (Satchi-Fainaro et al 2004). Polymer conjugation prevented TNP-470
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from crossing the blood brain barrier and decreased its accumulation in normal
organs and this should be the aim of these therapies.
The majority ofwork presented in this thesis does not involve the study of cancer.
However, it is necessary to understand tumour angiogenesis and therapies directed at






4) risk factors/prognostic indicators
5) proposed pathogenesis ofCAN development
6) treatment options
Overview
Chronic allograft nephropathy (CAN) is one of the most common causes of renal
transplant failure in the first post-transplant decade and the pathogenesis of this
condition remains unclear. CAN accounts for up to 40% of grafts which develop
progressive dysfunction and failure after the initial post-transplant months despite
appropriate treatment of acute rejection episodes that occur during this time (Paul
1999). Improvements in modern immunosuppressive therapy has resulted in dramatic
improvement in graft survival rates in the short term (the one-year cadaveric allograft
survival is around 90%) (Ponticelli 2002) but there has only been modest
improvement in the long-term graft survival rates. This provides a focus for the
current research.
The term chronic allograft nephropathy has evolved to reflect the multifactorial
nature of the pathogenesis of this condition in which immune and non-immune
factors are known to be implicated and the diagnosis is secured by a combination of
clinical and histological criteria.
Once diagnosed, the condition follows a variable clinical course that may result in
graft loss and a return to renal replacement therapy. At present, although recent
studies have suggested that optimisation of immunosuppressive regimens will
maximise graft function, in particular the use of calcineurin inhibitor sparing agents
thus limiting nephrotoxicity, there remains no definitive treatment for established
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CAN (Gonzalez-Molina et al 2002, Weir 2001, Weir et al 2001, Pilmore et al 2002,
Pretagostini et al 2001).
Mechanistic and molecular understanding of the pathogenesis ofCAN is needed if
novel therapeutic strategies are to be developed to prevent or delay its development.
Identification of risk factors in both donor and recipient may allow optimisation of
the graft and further understanding of the relative importance of various insults
sustained by the graft will lead to the development of new therapeutic strategies for
their prevention.
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Clinical diagnosis of CAN
The European Renal Association - European Dialysis Transplantation Association
(ERA-EDTA) created the European Best Practice Guidelines in 1998. More recently
published guidelines (Nephrology Dialysis Transplantation 2002) have focused on
the long-term management of the transplant recipient. These guidelines address
topics such as the organization of follow-up after the first transplant year, the
differential diagnosis of chronic graft dysfunction, the control of alloimmune and
non-immune factors and the management of de novo renal disease following
transplantation. A brief summary of these guidelines follows.
Organization offollow-up
Guideline A: All renal transplant recipients should undergo regular laboratory check¬
ups and regular out-patients visits.
Guideline B: All renal transplant recipients should be seen at least once a year in the
transplant centre where the transplant was performed or referred to a closer
transplant centre.
Such follow-up will allow for the specialist treatment of delayed complications after
transplantation and for the prompt diagnosis ofCAN.
Chronic graft dysfunction
This term represents a clinical diagnosis and is variably defined in the literature.
Consistent to many definitions of chronic graft dysfunction is that there is a
progressive decline in graft function after the first three post-transplant months as
shown by a rise in serum creatinine levels, the presence ofproteinuria or a decline in
graft glomerular filtration rate (GFR). Other clinical manifestations, such as the
presence of systemic hypertension, may coexist but are less specific to graft
dysfunction owing to its high prevalence (Raine 1995).
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Chronic graft dysfunction differs from delayed graft function which occurs at an
earlier stage. Delayed graft function is defined as the requirement of dialysis in a
specified post-operative period, usually the first week. Other studies also include
urine output and a decrease in serum creatinine as criteria to distinguish delayed graft
function from early function (Shoskes et al 1996). Although the two diagnoses are
distinct there is evidence to suggest that early graft damage and discrete events
secondary to vascular rejection and delayed graft function have an effect on the
development ofCAN (Nankivell et al 2001). The pathogenesis and risk factors for
the development of CAN will be discussed in greater detail below.
The EBPG guidelines reflect the established view of the scientific community with
the following recommendations:
Guideline A: Any significant deterioration in graft dysfunction should be
investigated using appropriate diagnostic tools and, ifpossible, therapeutic
interventions should be initiated.
Guideline B: Any new onset and persistent proteinuria of 0.5g/24h should be
investigated and therapeutic interventions should be initiated.
Premature death with a functioning graft is the most prevalent cause of graft loss in
non-censored graft survival analysis (Ponticelli et al 2000). The main difficulties that
arise with analysis of death-censored long-term graft survival are that not all failed
grafts are studied histologically and that, in those which are, more than one condition
may co-exist within the same graft. Data from a recent study of 197 failed grafts after
the first transplant year showed CAN to be the leading cause of failure with almost
50% of cases being attributed to it (death with a functioning graft was second most
common with 35% of cases attributed to this). The same study reported the death-
censored projected graft half-life to be 31.1 years (Ponticelli et al 2002).
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The differential diagnoses of chronic graft dysfunction, which can only be confirmed
following histological evaluation, are as follows:
- chronic allograft nephropathy
- transplant glomerulopathy
- acute rejection (can occur at any time)
- calcineurin inhibitor nephrotoxicity
- transplant renal artery stenosis
- ureteric obstruction
- recurrent or de novo renal disease
'Chronic allograft nephropathy' describes the structural and functional changes in the
graft that cannot be explained by other causes outlined above. It is characterized by a
variable but usually progressive decline in GFR over months or years (Paul 1993)
and up to 28% of patients will present with >0.5g proteinuria /24h (Massy 1996 et
al). Clinical distinction ofCAN from other conditions is not possible and requires a
diagnostic biopsy specimen with subsequent histological analysis. The presenting
features of other conditions may be similar to those seen with CAN e.g. proteinuria is
evident in the majority of cases of transplant glomerulopathy, therefore the use of
such criteria lack sensitivity or specificity. Indeed events such as late acute rejection
episodes may occur without clinical symptoms or signs and are only picked up
during routine follow-up.
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Histopathological features of CAN
Individual histopathological findings in CAN are not specific although in
combination a pattern of consistent changes is seen. These include graft vessel
arteriosclerosis, glomerular lesions and glomerular sclerosis, infiltration with
macrophages and lymphocytes, peritubular capillary basement membrane
multilayering (seen under electron microscopy), interstitial fibrosis and tubular
atrophy.
Graft atherosclerosis consists of concentric intimal thickening that affects large
arteries and arterioles and is often accompanied by a moderate degree of infiltration
of the vessel wall with macrophages and lymphocytes. The intimal thickening is
thought to result from the migration of (myo)fibroblasts from the media to the
intima, followed by local proliferation and deposition of extracellular matrix
proteins. In vitro study of endothelial cells challenged by allogeneic
lymphomonocytes shows they can promote the transdifferentiation of the functional
phenotype of smooth muscle cells' from contractile to synthetic myofibroblasts
phenotype (Amore et al 2001).
The glomerular lesions ofCAN are variable and include collapse of the glomerular
tuft, glomerular hypertrophy, mesangial matrix expansion and focal
glomerulosclerosis. Transplant glomerulopathy is described as a lesion where there is
enlargement of the glomeruli with swelling of the endothelial and mesangial cells,
infiltration of the glomeruli with mononuclear cells, mesangial matrix expansion and
widening of the subendothelial zone with interposition ofmesangial cells and matrix
(Hamburger et al 1964, Olsen et al 1992). In most grafts with CAN a non-diagnositc
pattern of immunoglobulin deposition is seen. (Paul 1999).
The composition of extracellular matrix proteins deposited in CAN include tenascin,
the extradomain A (EDA) isoform of cellular fibronectin, collagen type IV, laminin,
heparin sulphate, decorin and collagen III.
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CAN can be categorised in accordance with the Banff 97 working classification of
allograft pathology to give more detail regarding the histological findings (Solez et al
1993, Racusen et al 1999)(see table below). CAN has been graded by chronic
tubulointerstitial changes with or without specific vascular changes suggesting
chronic rejection. In the lesion scoring scheme, chronic vascular lesions are scored as
percentage arterial narrowing of the luminal area by fibrointimal thickening and
using this system it is possible to artificially define grafts as showing 'chronic
interstitial rejection' or 'chronic vascular rejection'. It has been shown that these two
groups have different risk profiles with potential prognostic implications (Sijpkens et
al 2001). A recent study of protocol biopsies taken at three months post-transplant
confirm that patients who show signs ofCAN with vasculopathy have a poorer 10
year graft survival than patients with biopsies showing CAN without vasculopathy
(Seron et al 2000).
As stated previously, one of the possible pitfalls with the analysis of graft biopsy
specimens is the existence of two or more conditions within the same graft as the
presence of co-morbid pathology will not allow the clinician to confirm graft
dysfunction to be entirely related to CAN.
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Banff 97 diagnostic categories for renal allograft biopsies (Racusen et al 1999)
1. Normal
2. Antibody mediated rejection. Rejection demonstrated to be due, at least in
part, to anti-donor antibody.
A. Immediate (hyperacute)
B. Delayed (accelerated acute)
3. Borderline changes: 'Suspicious' for acute rejection
4. Acute/active rejection
Grades IIA (less severe), IIB, IIA(includes vascular rejection), IIB and III.
5. Chronic/sclerosing allograft nephropathy
Grade I (mild) Mild interstitial fibrosis and tubular atrophy without (a) or
with (b) specific changes suggesting chronic rejection.
Grade II (moderate) Moderate interstitial fibrosis and tubular atrophy (a) or (b).
Grade II (severe) Severe interstitial fibrosis and tubular atrophy and tubular loss
(a) or (b).
6. Other
- Post transplant lympho-proliferative disorder
- Non-specific changes
- Acute tubular necrosis
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- Acute interstitial nephritis
- Cyclosporin or tacrolimus associated changes, acute or chronic
- Subcapsular injury
- Pre-transplant endothelial injury
- Papillary necrosis




- Obstruction/reflux, urine leak
- Other
In addition to the above, quantitative criteria exist for scoring
• tubulitis,
• intimal arteritis,
• mononuclear cell interstitial inflammation,





• mesangial matrix increase,
• vascular fibrous intimal thickening and
• arteriolar hyaline thickening.
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Protocol biopsies
Protocol biopsies are performed on patients with functioning renal grafts to provide
tissue for examination which gives both clinically relevant information that may
affect patient management as well as being a valuable tool to the researcher. Serial
protocol biopsies may be performed during the lifetime of the graft at time-points
decided on by individual transplant centres. Some institutions elect not to perform
protocol biopsies because it is a non-therapeutic intervention with potential patient
morbidity. Non-protocol biopsies are performed when there is clinical indication e.g.
deterioration in graft function.
Debate exists about the timing and number ofprotocol biopsies that should be
performed when following up a renal transplant recipient as concerns remain about
their reliability (Seron et al 2002). These specimens allow for the detection of
disease which is not yet manifested clinically and it has been shown that some degree
of CAN is present in 25% ofpatients at three months and 50% ofpatients at 2 years
post-transplant in whom there had been no adverse clinical events (Legendre et al
1998).
The use of protocol biopsies relies on being able to identify histological parameters
that may be used as primary efficacy variables. Intimal thickening and interstitial
widening have been shown to progress rapidly over the first four months following
implantation and slowly thereafter and may have a utility in this area (Moreso et al
2001). Early tubulointerstitial damage seen at three months profoundly influences
graft survival beyond 10 years and fibrointimal thickening of small arteries and
interstitial fibrosis at three months independently predict graft loss and decline in
renal function (Nankivell et al 2001). Furthermore is has been proposed that protocol
biopsies will have a use in the design of clinical trials aimed to prevent CAN and
may allow a reduction of sample size and the timing of follow-up (Seron et al 2000).
In biopsies taken from grafts where a clinical indication exists at a time of six months
or later following implantation the prognostic effect of arterial wall thickening is not
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seen (Freese et al 2001). This study highlights that the cohort ofpatients who have
protocol biopsies (i.e. all patients under follow-up in certain centres) is different to
the patient group in whom clinical manifestations of graft damage have prompted the
taking of a biopsy.
Whilst accepting that the use of both protocol and clinically-indicated biopsy
specimens is the most common means of obtaining human renal allograft tissue to
study there are two possible pitfalls here. First are the technical considerations such
as variability in terms of technique and processing of the sample. To a large extent
these variables can be minimised by the use of standardised procedures for the
handling of tissue. The second pitfall to consider is whether such biopsy specimens
are truly representative of the whole organ. This problem is highlighted by the study
ofCD31 immunohistochemical staining within human breast cancers which showed
that microvessel counts from biopsies did not correlate with the microvessel count
obtained from a cross-section of the whole gland (Jacobs et al 1998, Marson et al
1999). Similar investigation of observer variability and reproducibility of biopsy
specimens form part of the work of this thesis.
The use of animal models of disease can provide valuable information and these will
be briefly examined in the next section.
Introduction 30
Animal models ofCAN
Study ofprogression ofCAN may be optimised by the development of animal model
systems.
A rat model ofCAN exists using uninephrectomised Lewis rats as recipients and
Fisher 344 kidney allograft donors (Nagano et al 1997). A cardiac model of chronic
rejection in mice (heterotopic cardiac mouse transplantation ofCBA strain into
C57BL/6) was able to mimic the clinical characteristics seen in humans (Koglin et al
1999).
A mouse model ofCAN is under development in our research group. No tissue was
available for study during the time allotted to this study but will provide an excellent
method for undertaking investigation of the role of the endothelial cell and
macrophage in the development ofCAN. The model has been developed in the
United States and Canada (Mannon et al 1999). One strain ofmice e.g. B.10.A will
be used as donors and kidneys will be transplanted into a different strain of recipient
mice e.g. B.10.BR with only one allele difference so that acute rejection episodes are
avoided. As non-rejecting isograft controls, kidneys will be transplanted between
litter mates. The donor kidney, ureter and bladder will be harvested en bloc and
transplanted onto recipient abdominal aorta, inferior vena cava and bladder. The right
native kidney will be removed at the time of the transplant and a left nephrectomy
performed seven days later. Renal function will be assessed at various time points
following transplantation and will include proteinuria, serum creatinine and
creatinine clearance. Various histological assessments of the kidneys will be made
following sacrifice of the mice.
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Risk factors and prognostic indicators of CAN
Until molecular understanding of the pathogenesis ofCAN is better defined and
novel therapeutic strategies are under development, any advances in long-term graft
survival will come from the optimisation of donor and recipient factors. Donor or
host age, gender and co-morbidity are difficult to optimise whilst there is a premium
on finding sufficient numbers ofmatched donors as is the case in this country (UKT
2002). Refinements of existing and newer immunosuppressive therapy will be
considered in a later section.
Previously this progressive decline in graft function had been termed 'chronic
rejection' reflecting the belief that it resulted from a continuous immunological
aggression of the host against the allograft. The term chronic allograft nephropathy
has evolved to reflect the fact that both allo-antigen dependent and allo-antigen
independent mechanisms may participate in the development of graft dysfunction
(Ponticelli 2000). It is likely that CAN develops as a result of a combination of both
immunological and non-immununological factors.
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Immunological Factors -Alloantigen-dependent
Chronic rejection (CR) is an antigen-dependent immune process leading to the
lesions observed in CAN. Allotransplantation of organs results in activation of the
immune system by alloantigen-dependent processes and recognition of foreign
antigens on cells of the graft results in activation of specific immune responses
(Joosten et al 2003). As such, all recipients of an allogenic kidney graft should
receive life-long immunosuppressive medication (see below).
Several studies have shown that patients who experience episodes of acute rejection
(especially those occurring after the first 4 months) have a higher incidence of CAN
and graft loss (Shishido et al 2003, Massy et al 1996, Baboolal et al 2002).
The Collaborative Transplant Study (CTS) data presented at the 17th World Congress
of the Transplantation Society in 1999 shows a strong association of the number of
HLA-A+B+DR mismatches with graft survival rate. HLA (human leucocyte antigen)
matching has been shown to have a beneficial effect on long-term graft survival and
graft half-life (Opelz et al 1999) and the best results were observed with HLA-
identical sibling donors (Teraski et al 1995). After organ transplantation the immune
system of the recipient encounters various foreign antigens in the graft. All donor
antigens that differ from those of the recipient evoke an immune response if
presented to the immune system. A possible explanation as to why mis-matching
may lead to CR is that HLA incompatibility increases the immunogenicity of the
graft and triggers a continuous subclinical aggression against the allograft, eventually
resulting in its progressive loss. Antigen presentation may follow one of two
pathways - direct and indirect.
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Direct antigen presentation
Donor alloantigens are presented to recipient T-cells by donor-derived antigen
presenting cells (APCs). This will mainly result in the activation of type-1 responses
and thus activation of CD8+ cytotoxic T-cells.
direct




Infiltrating recipient-derived APCs present donor alloantigens (after their uptake) to
recipient T-cells activating CD4+ T-cells. It has also been suggested that indirect
presentation results in the production of alloantibodies by B-cells (Joosten et al
2003)(see below).
Direct presentation is thought to be mainly involved in acute rejection, whereas
indirect presentation is suggested to be more important for CR (Waaga et al 2000).
Induction of an immune response after recognition of antigens by either method
requires a second or co-stimulatory signal between the APC and T-cell e.g. the
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CD40-CD154 pathway. These co-stimulatory signals are essential for the induction
of immune responses and thus for transplant rejection and their blockade in allograft
models improves graft survival (Sayegh et al 1998).
Immune activation can be initiated not only by the recognition of specific antigen
('acquired immunity') but also by the recognition ofnon-specific injury ('innate
immunity'). Such non-specific injury that occurs during transplantation (e.g.
ischaemia) initiates inflammation by recruitment of lymphocytes, macrophages and
dendritic cells. This triggers the production of the co-stimulatory pathways that
stimulate T-cells which are central to the process of CR (Lu et al 1999). Furthermore,
studies in rats have shown brain death of the donor up-regulates various lymphocyte
and macrophage derived cytokines on somatic organs thus increasing their
immunogenicity (Takada et al 1998).
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The role of alloantibodies in CAN
Alloantibodies seem to be important mediators of CR. Antibodies that have been
recognised as significant are those against HLA, perlecan, collagen, mesangial cells
and endothelial cells (Joosten et al 2003). Renal transplant recipients with anti-HLA
antibodies have been found in 12-60% of recipients and these patients were 5 to 6
times more likely to develop CR (Sumitran-Holgersson et al 2001, McKenna et al
2000). Antibodies against endothelial cells have been found in renal transplant
recipients before and after transplantation (Ball et al2000). In a cohort of patients
with at least one failed graft, 14% had endothelial cell-specific antibodies compared
with 3% for recipients with stable function (Perrey 1998). Endothelial cell activation
induced by antibodies could also contribute to increased extravasation of allo-
immune immunocompetent cells to facilitate rejection.
Deposition of immunoglobulins in the graft is transient and difficult to detect but
since antibody binding results in deposition of complement, the more stable
complement split product C4d can be used as a marker for humoral rejection. In late
allograft biopsies C4d deposits were detected in one third of those studied. However
in kidneys that already had advanced lesions ofCR, glomerular basement membrane
lesions or allograft arteriopathy, C4d deposits were found in 60% of biopsies
(Mauiyyedi et al 2001). The high percentage ofC4d positivity implies a role for
antibodies in the pathogenesis of these lesions. The presence ofC4d in biopsies
correlated with anti-donor HLA antibodies; 88% of patients with C4d deposits also
had these antibodies in their circulation (Mauiyyedi et al 2001, Lederer et al 2001).
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Non-alloimmune Factors - Alloantigen-independent
• Advanced donor age - An analysis using the UNOS Scientific Renal Transplant
Registry (Terasaki et al 1997) demonstrated a strong effect of donor age on long-
term outcome and graft half-life and this was attributed to a relative deficiency in the
number of nephrons with regard to the recipient's metabolic demands.
• Glomerular hyperfiltration - It is hypothesised that, as a consequence of decreased
renal mass that occurs after transplantation, ensuing glomerular hyperfiltration in the
remaining nephrons provokes progressive glomerulosclerosis leading to graft failure
(Sola et al 2002).
• Delayed graft function - Transplants with prolonged ischaemic exposure and
delayed graft function experience inferior long-term outcome (Shoskes et al 1996).
• Proteinuria - Patients who subsequently lost their grafts to chronic rejection more
commonly had proteinuria (>0.5g/24hr) in the first 24 months after transplantation
and that proteinuria was an independent risk factor for chronic rejection (Massy et al
1996).
• Arterial hypertension - The degree of hypertension during the first 24 months after
transplantation has been shown to be a risk factor for developing chronic rejection
using univariate analysis, but the effects of hypertension were not independent of
other risk factors in multivariate analysis (Massy et al 1996). Although it is likely
that adequate control of the hypertension associated with chronic rejection will
improve graft outcome this is yet to be proven in controlled trials (Raine et al 1995).
• Hyperlipidaemia - Hypertriglceridaemia (>200 mg/dl) has been shown to be an
independent risk factor for chronic rejection and that this effect was in turn
independent ofpre- and post-transplant diabetes mellitus (Massy et al 1996). Graft
biopsies from patients with elevated cholesterol levels often display more severe
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chronic damage than biopsies from patients with lower cholesterol levels, although
this has not been shown in all studies (Cardinal et al 2002, Paul 1999).
• CMV infection - Cytomegalovirus disease has been shown to be associated with
early graft dysfunction (Tong et al 2002) and to be an independent risk factor for
CAN (Sola et al 2003). Graft outcome and loss has not been shown to be primarily
attributed to CMV infection but rather determined by acute rejection episodes and
the development ofCAN (Kashyap et al 1999). CMV disease is however associated
with early graft dysfunction (Tong) and is preceded by treated episodes of acute
rejection in 65% of cases. CMV infection is probably associated with CAN
suggesting that an increase in viral load leads to a higher risk of developing CAN
(Sola et al 2003).
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Proposed pathogenesis of CAN
Inflammatory response to graft injury
Renal injury results in structural damage and impairment of function. A stereotypical
inflammatory response occurs following renal injury and comprises:
• influx of lymphocytes, monocytes and macrophages
• proliferation of fibroblasts
• deposition of extracellular matrix material
• scar formation
• tissue restoration
This tissue remodelling is the beneficial effect of the inflammatory cascade but it
also causes inhibition of cell proliferation and apoptosis with cell loss and this is
potentially deleterious to the affected tissue. Furthermore, fibrosis and scar formation
results in disruption or loss of the normal microvascular skeleton which is likely to
lead to further tissue hypoxia.
The macrophage has an important role in the outcome of inflammation (Morrissette
et al 1999) and significant increases in macrophages and myofibroblasts occur in
early renal biopsy specimens in patients who later develop CAN (Pilmore et al
2000). Macrophages may be stimulated by both humoral and cellular immunity and
non-immune mechanisms and once activated their effects are pleotrophic (Croker et
al 1996). These are summarised on the next page.
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Macrophage activation
• T-cells and macrophages have a reciprocal relationship: T-cell derived IL-2 and
IFN-y can stimulate macrophage activation whereas macrophages play a role in T-
cell activation by producing T-cell activators such as IL-1 and as antigen presenting
cells.
• Intrinsic renal cells may directly stimulate macrophages e.g. glomerular endothelial
cells produce monocyte chemoattractant protein 1 (MCP-1).
• Antibody and complement binding and activation stimulate macrophages.
• Autocrine and paracrine loops exist for macrophage activation. MCP-1 and IL-1 are
produced by macrophages which also have receptors for these cytokines and are
stimulated by them.
Effect ofmacrophage activation
• Macrophages produce a variety of factors which affect blood vessels in the short
and long term e.g. platelet derived growth factor (PDGF), vascular endothelial
growth factor (VEGF), nitric oxide (NO), thromboxane, transforming growth factor-
p (TGF-p).
• Interstitial cells proliferate and produce matrix proteins in response to macrophage
products.
• Macrophage activation in quiescent renal allografts augments rejection (Nagano et
al 1997) and the presence of glomerular macrophage infiltration predicts a
significantly worse graft outcome (Ozdemir et al 2002). This may be as a result of
deleterious rather than reparatory cell loss and there is in vitro evidence shows that
macrophages can induce endothelial cell apoptosis (Lang et al 1993, Lang et al 2003
unpublished).
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Ischaemia-reperfusion injury and donor brain death can induce or amplify the
immune response via the production of reactive oxygen species, pro-inflammatory
mediators and growth factors, increased expression of adhesion molecules and
upregulation of both HLA class-I and class-II molecules (Stoica et al 2002, Szabo et
al 1998, Takada et al 1998).
After ischaemia-reperfusion tissue injury, interleukins 12 and 18 induce interferon-y
with subsequent upregulation ofMHC class-I and class-II antigens and activation of
the endothelium, triggering costimulatory molecules and T cell facilitation (Szabo et
al 1998, Daemen et al 1999). This, together with tubular epithelial cell apoptosis
(Chien et al 2001, Daemen et al 2002), results in increased recruitment of
inflammatory cells and inflammatory processes which can further facilitate
alloantigen dependent processes described above. Thus these can be considered as
progression factors for CAN. Cytokine excess may be a contributory factor. It is
proposed that repetitive injury over a short period of time results in excessive
production of fibrogenic cytokines including transforming growth factor (3 (TGF-(3)
(Cuhaci et al 1999) and platelet derived growth factor (PDGF). These cytokines
promote excessive deposition of extracellular matrix proteins with associated fibrosis
as is seen in CAN.
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Vascular injury
The most widely described hypothesis to explain CAN is that vascular injury is the
trigger for the inflammatory response to injury detailed above. Indeed vascular
rejection correlates most strongly with graft prognosis (Van Saase et al 1995).
Furthermore, studies of grafts with CAN show different risk profiles for interstitial
versus vascular types of chronic rejection with biopsies showing CAN with
vasculopathy have a 10 year graft survival that is half that of CAN without
vasculopathy (Sijpkens et al 2001, Seron et al 2000).
Endothelial cell damage results in a combination of increased endothelial
permeability, increased exposure of host antigens and a prominent inflammatory
response by endothelial cells themselves (Akyurek* 1995). Angiogenesis is likely to
be stimulated as a result of hypoxia following endothelial cell loss. A recent study
has demonstrated increased vascularity in biopsies from grafts with signs ofCAN
versus both acute rejection and normal kidney. The increase was observed in
association with the development of interstitial fibrosis and poor outcome (Ozdemir
et al 2002). VEGF has been shown to be up-regulated in CAN and its expression
correlated with macrophage expression (Pilmore et al 1999).
Vessel wall proliferation and vascular sclerosis result from growth regulating
cytokines produced by endothelial and smooth muscle cells in response to previous
vessel wall injury, resulting in activation of self-amplifying autocrine and paracrine
activation cascades. If vessel wall lesions are considered to be the primary lesions in
CAN, the tubulointerstitial and glomerular lesions that are seen may be considered as
secondary or collateral to these vascular lesions.
Conflicting evidence exists which suggests that CAN emerges as a result of
disruption of the graft vessel lymphatics (Demetris et al 1997) and that obstruction of
the lymphatics that drain the vessel wall will cause the vessel wall lesions as
observed in CAN (Solti et al 1991).
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It is likely that CAN emerges as a consequence of primary vascular or lymphatic
lesions or a combination of the two.
Introduction
Premature senescence and donor age
Chronic allograft nephropathy may represent the exhaustion or senescence of graft
endothelial cells or tubular cells. Senescence can best be thought of as 'wear and
tear' of cells. Somatic cells in culture can undergo only a limited number of divisions
after which they become senescent resulting in reduction in processes such as energy
generation and replication to shut down. Histologically this is characterised by
membrane damage and cellular atrophy and the process may be accelerated by
immune-mediated and/or non-immune injuries (Halloran et al 1999). In the
development ofCAN it could therefore be argued that the fibrosis that is observed
may be as a result of a loss of regulatory control of inflammation and healing by
senescent graft cells which are ultimately exhausted.
As described above, (Terasaki et al 1997) advanced donor age correlates with
inferior long-term graft outcome in some studies (Alexander et al 1994), although
conflicting hypotheses have been presented to explain this, including the concept of
senescence or that increased donor age and reduced renal mass lead to hyperfiltration
and glomerulosclerosis (Brenner et al 1992). Micropuncture studies in rats have
shown glomerular hypertension to exist in kidney grafts with CAN (Kingma et al
1993). However in the same study glomerular hypertension in syngeneic grafts did
not result in CAN. This suggests that glomerular hypertension is a permissive or
progression factor in the pathogenesis ofCAN rather than a direct cause. This
statement is further supported by the results of two studies that failed to demonstrate
an indirect effect of donor age on graft outcome. An equivalent risk of graft failure
was demonstrated when comparing donors aged 75 years from the period 1994-1997
with donors aged 30 years from the period 1983-1990 (Roodnat et al 1999). If the
pathogenesis of CAN is to be assumed to be unchanged between these two time
points then it is impossible to support a hypothesis that an ageing donor kidney with
reduced renal mass is solely responsible for the development ofCAN and that the
effects of improved immunosuppression and control of immune mediated reactions
have a greater importance than other risk factors. The second study (Kerr et al 1999)
demonstrates that excellent results from older donors can be obtained when they are
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HLA-related living donors. Disproportion between donor and recipient size has not
conclusively been shown to alter graft outcome.
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Immunosuppression and CAN
Until the 1980s standard immunosuppression consisted of corticosteroids and
azathioprine, complemented in some centres with the prophylactic use of anti-
lymphocyte antisera in the first few post-transplant weeks (Paul 1999). The first two
agents are still regularly of use in current practice together with additional newer
treatments but caution must be exercised when interpreting data regarding the impact
on the development ofCAN.
Unfortunately there is a relative lack of randomised trials with sufficient population
sizes and robust follow-up information to fully assess the impact of various
immunosuppressive drug regimes on long term outcome. Reports from both the
National Institute for Clinical Excellence (NICE) and British Transplantation Society
(BTS) from the last two years concluded that there are insufficient data to permit
specific recommendations regarding immunosuppressive therapy and that all
currently available immunosuppressive drugs should remain freely available for use
by transplant centres. Formal randomised controlled trials can be difficult to
construct owing to heterogeneity of patient population and relatively small size of
sub-groups as well as the significant and variable side effect profile of the drugs.
Furthermore, the impact of newer treatments such as mycophenolate mofetil on the
development of chronic allograft nephropathy will only become apparent over the
next few years when longer follow-up periods are available.
As well as the maintenance regimen of oral immunosuppressive therapy many
patients receive anti-T cell antibody therapy peri-operatively e.g. anti-thymocyte
globulin (ATG), and the impact of these drugs on development ofCAN has not been
extensively reported.









In the Collaborative Transplant Study database the five year graft survival rates were
significantly better in patients who had been switched from CsA, steroids and
azathioprine to steroid-free maintenance immunosuppression with CsA, with or
without azathioprine (Opelz et al 1994, Opelz et al 1995). This suggests that the
detrimental effect of corticosteroids exceeds their potential benefit on long term graft
outcome, although only 10% of the patients reported were treated with the steroid
free regimens and it is likely that these were low risk patients. More recently it has
been shown that steroids can be safely withdrawn in patients treated with
mycophenolate mofetil (Grinyo et al 1997) but with no long term data to assess its
impact on chronic allograft nephropathy.
Other studies have attempted to address this issue of steroid withdrawal and its effect
on short and long term graft outcome without arriving at a consensus decision. As
such the use of corticosteroids (both dose and duration) will continue to be a matter
for each individual transplant centre to decide upon until data becomes available




During the 1980s the introduction of the calcineurin inhibitor cyclosporine (CsA)
resulted in a decrease in the incidence of acute rejection episodes and an improved
one year graft survival rate. However United Network for Organ Sharing (UNOS)
data (Gjertson et al 1992) demonstrated that it did not affect the rate of graft loss
occurring after the first year (Terasaki et al 1992). It is likely that the
immunosuppressive efficacy is offset by its nephrotoxic side effects (Myers et al
1984) or that inadequate doses have been prescribed as a result of concerns regarding
its nephrotoxicity (Burke et al 1994). A third possibility is that the drug may have no
effect on chronic allograft nephropathy.
When referring to the United Network for Organ Sharing (UNOS) data the presence
of variables affecting graft survival other than immunosuppression makes evaluation
of the impact of CsA introduction on long term graft outcome more difficult. There
were a number of differences between the time periods assessed (1975-79 pre-CsA
versus 1985-90 with CsA). The expansion in the numbers of transplant centres away
from a smaller number of expert centres may be an important variable as well as
changes in clinical practice experienced. In the past most transplant recipients were
young, without significant comorbidity and received the kidney from a young donor.
More recently, recipients of renal transplants have been older and with comorbid
conditions such as diabetes, cardiovascular disease or other systemic diseases
(Ponticelli 2000) and this will have affected graft survival in the time frame of the
data.
The effect of the introduction of cyclosporine therapy in the 1980s on the treatment
ofpatients with renal transplant has been described together with concerns over
biases between the two time periods compared in the UNOS study. This may have
skewed results to support a hypothesis that cyclosporine therapy confers no long
term benefit on graft outcome. The most recent UNOS data now reports an increase
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in cadaveric graft half life to 10.4 years (from 7.8 years in cyclosporine treated
patients between 1985 and 1990) for renal transplants performed between 1995 and
1996 (Ponticelli 2000). By comparing this figure with experience from other
controlled and uncontrolled studies from recent years where patients have been
receiving cyclosporine it can be seen that excellent results can be obtained. A study
of 632 cyclosporine treated patients showed a graft half life of 19.9 years with a
death censored half life of 24.8 years (Montagnino et al 1997). A 12 centre
collaborative trial which investigated three different modalities of cyclosporine
administration in cadaveric renal transplant recipients showed mean graft half lives
of 16.4, 12.6 and 19.0 for single, double and triple therapy respectively (Tarantino et
al 1998). A study of young renal transplant recipients (<50 years of age) treated with
cyclosporine reported a graft half life of 21.8 years and a review of the data of the
Collaborative Transplant Study showed a half life ofmore than 17 years for first
cadaveric grafts treated with cyclosporine based triple therapy (Opelz et al 1995).
These studies suggest that certain groups of cyclosporine treated renal transplant
recipients have graft survival far in excess of the figures quoted in the UNOS studies.
Furthermore the preparation of cyclosporine used in most transplant centres has
changed to a microemulsion in recent years with an improved pharmacokinetic
profile (Goel et al 2002). Chronic allograft failure (CAF), acute rejection rates and
graft survival have been compared between different preparations of cyclosporine
and with tacrolimus. Both tacrolimus and cyclosporine microemulsion are associated
with a significantly better adjusted CAF-free survival at 4 years (Meier-Kriesche et
al 2002) with improved graft survival compared with the older conventional
cyclosporine formulation (Boots et al 2001).
Despite the fact that cyclosporine is undoubtedly a nephrotoxic agent there is
evidence that when administered appropriately a deleterious effect on long term graft
outcome may be avoided (Burke et al 1994). In contrast a prospective trial of
conversion from cyclosporine to azathioprine after the third month post¬
transplantation showed a trend toward better patient survival, graft survival and
longer uncensored half life at 13 year follow-up in the group converted to
azathioprine but without reaching statistical significance. Chronic allograft
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nephropathy was present in 12% of cyclosporine treated patients compared with 8%
of the azathioprine-treated group (Paul 1999). Another study confirms short term
patient and graft survival have improved with the use of cyclosporine but that this
effect is not maintained in the long-term (Marcen et al 2001).
Reduction in the dose of calcineurin inhibitors in patients with histological evidence
of nephrotoxicity resulted in a sustained improvement of renal function (Pilmore et al
2002) and such an intervention was safe, well tolerated and associated with minimal
risk of acute rejection (Weir et al 2001).
Tacrolimus
Tacrolimus (or FK-506) is another calcineurin inhibitor and offers an alternative to
cyclosporine. Both this and CsA can cause histological and functional renal
impairment that is difficult to distinguish from chronic allograft nephropathy (Myers
et al 1984, Connolly et al 1994).
In a randomized open-label trial comparing cyclosporine A with tacrolimus, one year
graft and patient survival rates were similar although the tacrolimus-treated group
showed a significant reduction in the incidence and severity of biopsy proven acute
rejection episodes (Pirsch et al 1997).
The effect of conversion to tacrolimus from cyclosporine on long term graft outcome
and chronic allograft nephropathy is unclear and conflicting evidence has been
presented. UNOS kidney transplant registry data shows a significantly longer
projected graft half life in patients treated with tacrolimus compared with those
treated with cyclosporine A (Gjertson et al 1995). With the addition of
supplementary information these data were further confirmed showing that
tacrolimus improves graft survival and half life (Katznelson et al 1996). However
these data have been contrasted with analysis of the Collaborative Transplant Study
(Opelz et al 1999) which show that immunosuppression with tacrolimus results in
graft outcome that is comparable to, but not significantly better than, conventional
cyclosporine A. It is important to consider that these studies have compared
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tacrolimus with non-microemulsion CsA ('Sandimmune')which has been shown to
be less efficacious than the newer microemulsion CsA ('Neoral'). More recently a
study with longer follow-up (6 years) has shown that patients receiving tacrolimus
had significantly greater 6 year graft survival and a higher projected graft half life
than those receiving cyclosporin microemulsion (Jurewicz et al 2003). A smaller
Italian study further supports conversion to tacrolimus to be safe and efficacious
(Pretagostini et al 2001) and a randomised trial comparing cyclosporine
microemulsion to tacrolimus revealed an association with increased allograft fibrosis
and significantly higher serum low-density lipoprotein cholesterol levels in the
cyclosporine treated group (Murphy et al 2003).
The difference in effect of these two drugs may be due to differing expression of the
pro-fibrotic cytokine transforming growth factor p (TGF-p). A prospective study of
51 patients randomised to cyclosporine or tacrolimus revealed a ten fold increase in
TGF-P mRNA in protocol biopsies from the cyclosporine treated group which was
associated with interstitial fibrosis (Baboolal et al 2002). The same study concluded
that calcineurin inhibitors (and acute rejection episodes) were the most important
factors contributing to early renal structural injury.
Introduction 52
Azathioprine
The Collaborative Transplant Study registry showed no difference in the estimated
half life of kidney transplants in patients treated with CsA and corticosteroid only
compared with CsA, corticosteroid and azathioprine, suggesting that azathioprine
does not improve long term outcome (Opelz et al 1995). These findings have been
repeated in other studies and meta-analyses.
Mycophenolate mofetil (MMF)
Studies addressing whether the use ofmycophenolate mofetil affects long term graft
survival, patient survival or the development of chronic allograft nephropathy are yet
to be completed as follow-up times are too short. It is known that MMF in
conjunction with CsA decreases the incidence of acute rejection in the first six
months after transplantation by approximately 50% compared with placebo or
azathioprine (European MMF trial). There are also studies which have looked at
grafts treated with MMF at three years post-transplantation which suggest better graft
survival than those treated with azathioprine (Ojo et al 2000) (Meier-Kriesche et al
2001a) and that a reduction in the risk of chronic allograft nephropathy occurs
independently of acute rejection episodes (Meier-Kriesche et al 2001b).
In patients who have chronic, progressive deterioration of renal function after
transplantation the addition ofMMF with reduction of cyclosporine dosage is well
tolerated and results in a short term improvement in renal function (Weir et al 1997).
This improvement in renal function with the use ofMMF to 'cover' dose reduction
of cyclosporine has been described elsewhere and provides stronger
immunosuppression than by using azathioprine (Jain et al 2001). Furthermore it has
been shown that the improvements are achieved irrespective of changes in blood
levels of cyclosporine A (Gonzalez Molina et al 2002). Adverse effects associated
with MMF include gastrointestinal upset and, in combination with tacrolimus,
neutropenic sepsis (Jain et al 2001, Metcalfe et al 2002).
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MMF acts to inhibit the de novo synthesis ofpurines which are crucial to cell cycling
of T and B cells. It therefore blocks the clonal expansion of B and T cells preventing
antibody production and the generation of cytotoxic T cells as well as other effector
T cells (Mele et al 2000). In cardiac transplantation patients treated with MMF
produced fewer anti-vimentin antibodies than patients treated with azathioprine
(Rose et al 2002). These data suggest that MMF prolongs graft survival due at least
in part to a decrease in the production of alloantibodies. However as mentioned




The recent introduction of the potent immunosuppressive agent sirolimus has
afforded an opportunity to develop a regimen designed to maximize prophylaxis of
early acute rejection without drug-induced nephrotoxicity. Sirolimus, like
cyclosporine, is a macrolide with potent antilymphocyte activity. Unlike
cyclosporine it complexes with a different cytosolic immunophilin (FKBP12),
resulting in suppression of cytokine driven T cell proliferation by inhibiting
progression from the Gi to the S phase of the cell cycle.
The three approaches of CNI elimination, avoidance or substitution have been
recently attempted each with the goal of reducing CNI induced nephrotoxicity. The
term CNI Avoidance implies a de novo immunosuppressive regimen without a CNI
and employs the use of one to three maintenance agents. The term CNI Substitution
describes the practice of using an alternative to a CNI drug in a maintenance
regimen. The many combinations ofmaintenance regimens now available can make
direct comparisons between initial regimens problematic. A potential penalty for
such CNI free immunosuppression is, of course, increased rates of acute (and
perhaps chronic) rejection, which would obviate the benefit of alternative regimens.
Early cyclosporine withdrawal using sirolimus has been shown to be followed not
only by an improvement in renal function, but also by a reduction in the rate of
progression of chronic pathologic allograft lesions and in the appearance of new
cases of CAN (Ruiz et al 2003). This effect is especially important in the case of
tubular and interstitial lesions, probably as a consequence of a reduction of CyA
nephrotoxicity. It is possible that this beneficial effect might be responsible for better
graft outcome after longer follow-up periods (Flechner et al 2003). This is supported
by a smaller study (40 patients) which demonstrated fewer histological signs of
chronic damage, especially vascular injury, in patients who had sirolimus
immunosuppression after withdrawal of calcineurin inhibitor therapy at 3 months
after transplantation (Stallone et al 2003). The use of sirolimus as a CNI sparing
agent, rather than as part of CNI-free regimens, has a more limited use. In a study of
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70 patients there were higher incidences of acute rejection and histological signs of
CAN at 1 year in patients randomized to a CNI sparing regime (sirolimus, MMF and
dose reduced tacrolimus) compared with a CNI free regime (sirolimus and MMF). A
further study of 31 patients which compared CNI dose reduction and introduction of
sirolimus as a CNI sparing agent demonstrated no functional, molecular or
histological improvements at 1 year compared with a standard CNI based regime
(Saunders et al 2003).
Rapamycin (sirolimus) has been shown to have actions that can disrupt angiogenesis.
The P13K/Akt signalling pathway plays a critical role in regulating basic cellular
functions including cell proliferation and angiogenesis and mTOR (mammalian
target of rapamycin) is a downstream mediator in this pathway (Chan et al 2004). In
ovarian cancer cells rapamycin has been shown to induce G(l) cell cycle arrest and
inhibit expression of important cyclins (Gao et al 2004). Similarly it has been shown
that the chronic myeloid leukaemia oncogene BCR/ABL induces VEGF gene
expression and its transcriptional activator HIF-1 alpha through a pathway involving
P13K and mTOR and that this expression is inhibited by addition of rapamycin and
LY294002 (Mayerhofer et al 2004).
Rapamycin may also inhibit angiogenesis through an alternate pathway. Functional
angiogenesis induced by fibroblast growth factor-2 is dependent upon the platelet
derived growth factor receptor-alpha (PDGFRalpha)-p70S6K signal transduction
pathway in mesenchymal cells. Rapamycin inhibits p70S6K and in a murine model
has been shown to shut down the sustained expression ofVEGF and hepatocyte
growth factor (HGF). In each tumour tested, rapamycin constantly led to tumour
dormancy via silencing of the PDGFRalpha-p70S6K pathway (Tsutsumi et al 2004).
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Summary
Analysis of these studies confirms that there is no consensus as to the use of one
particular immunosuppressive drug regimen compared to another. This decision will
remain at the discretion of the individual clinician and transplant centre.
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Novel treatment options
Currently there is no established maintenance immunosuppressive regimen that
decreases the incidence of chronic allograft nephropathy in humans.
Experimental animal studies have shown that immune tolerance prevents chronic
allograft failure; in skin and cardiac grafts by CD-28 and CD-40 blockade (Larsen et
al 1996) and with T-cell co-stimulation blockade (see above) in renal allografts
(Azuma et al 1996). There is, as yet, no evidence that this therapy will be feasible in
humans.
Alternatives to immune modulation involve the use of non-immunosuppressive drugs
such as somatostatin analogues (Hayry et al 1993), eicosanoid and platelet activating
factor inhibitors (Hayry et al 1993), heparinoids (Aziz et al 1993), insulin-like
growth factor antagonists (Hayry et al 1995), oestrogens (Lou et al 1996a) and nitric
oxide donors (Lou et al 1996b). Angiotensin receptor blockers have also been tested
(Furukawa et al 1996) as have angiotensin-converting enzyme (ACE) inhibitors
(Benediktsson et al 1996) and one retrospective clinical study has shown ACE
inhibitors to be beneficial in chronic allograft nephropathy (Barnas et al 1996). As
described above, systemic hypertension and hyperlipidaemia post-transplantation
should be treated appropriately (Raine et al 1995, Massy et al 1996) although there is
no evidence to show that this will reduce the rate of graft loss.
The major problem facing future investigators is the design of trials with sufficiently
large sample size, long follow-up periods and clearly defined end-points if these
advances are to be converted into clinical benefit.
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Suggested current management
Management ofpatients should take place in specialist, expert transplant centres.
Avoidance of graft damage as a result of ischaemia-reperfusion injury and ensuring
good HLA matching with consideration of preferential use of living related donors
should optimise graft peri-operative variables.
Undertaking aggressive management of acute rejection episodes (at whatever time)
to ensure complete reversal of graft function should be standard practice. When
choosing maintenance immunosuppression regimen, minimizing the use of
nephrotoxic agents (such as calcineurin inhibitors) and corticosteroids should be the
aim. Consideration of the use of surveillance biopsies must also be employed.
The provision of organs for transplantation is a simple case of supply and demand
with demand out-stripping supply in the UK at present (UKT). Most discussions of
the supply-demand dichotomy focus on the supply side of the equation however
attempts to diminish demand are just as important. Any course of action that
prolongs the functional survival of already transplanted kidneys will diminish the
demand for retransplantation. In fact, significant prolongation of live donor kidney
transplant survival may obviate the need for some patients to ever enter the waiting
pool for scarce cadaveric organs. There are also medical economic advantages to
prolonged graft survival. Recent analyses have demonstrated that initial increases in
the adjusted costs (compared to maintenance dialysis) of renal transplantation are
eclipsed after 2 years of graft survival. Beyond this interval savings to health care
systems begin to accrue. Therefore, prolongation of graft survival is beneficial to
both individual recipients and those who fund health care (Flechner et al 2003).
This thesis adds to the body of knowledge about the development ofCAN.
Ultimately work in this field will result in improved management ofCAN with the
benefits described above.
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Aims of the thesis
To determine changes in vascularity which occur in diseased human parathyroid
tissue and during the development of chronic allograft nephropathy.
The aims are addressed sequentially:
1. To investigate changes in vascularity between normal parathyroid
tissue, hyperplasia and adenoma and to seek an association with the
endothelial cell mitogen VEGF.
2. To undertake reproducibility experiments of the methodology used to
assess vascularity.
3. To validate the study of changes in vascularity in kidney disease with
the use of renal biopsies.
4. To examine changes in vascularity that occur during the development
of chronic allograft nephropathy and to seek an association with
endothelial cell proliferation and macrophage infiltration.
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Chapter 2: Materials and methods
In order to achieve the aims, five main studies have been performed described below.
Methods involved in the studies will be described in this chapter.
1. Vascularity of normal parathyroid, hyperplasia and adenoma were
compared using immunohistochemistry. The expression ofVEGF protein
and mRNA were investigated using immunohistochemistry, Western
blotting and in situ hybridisation.
2. i) Observer variation and reproducibility ofmicrovessel counts (MVCs)
was compared between the two principal investigators.
ii) The use ofmicrovessel counts in renal biopsies was examined by
comparing MVCs in kidney biopsies with cross section specimens from
the same kidney.
3. Changes in vascularity, endothelial cell proliferation and macrophage
infiltration between normal kidney and allograft nephrectomies performed
because of chronic allograft nephropathy.
4. Sequential assessment of changes in vascularity, endothelial cell
proliferation and macrophage infiltration during the development of
chronic allograft nephropathy using allograft biopsies.
Similar methodologies have been adopted throughout the thesis based on obtaining
specimens of human parathyroid glands and specimens of kidneys in the form of
biopsies or excision specimens. Sections were immunohistochemically stained with
antibodies to the CD31 elements of the endothelial cell, to VEGF and to proliferating
cells (MIB-1 antibody to Ki-67). Assessments were then made by microvessel
counting or by estimation of the percentage of cells staining. Western blotting and in
situ hybridisation were only performed on parathyroid tissue to assess expression of
VEGF.
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Methodological details describing aspects of the method common to all studies,
including histology and immunohistochemistry are presented first. This will be
followed by sections corresponding to each study performed. Full details ofmaterials
used are described in the Appendix to this chapter.
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Common methodologies - Histological evaluation
CD 31 immunohistochemistry- APAAP method
Tissue sections were dewaxed in xylene, rehydrated in descending concentrations of
ethanol and placed into deionised water. Antigen retrieval was achieved using
protease (Protease XXIV, Sigma) at 37°C for exactly 20 minutes. Sections were
loaded onto cover plates (Thermo Shandon) and DAKO serum-free protein block
was applied for 30 minute incubation followed immediately with primary antibody
(mouse monoclonal anti-human CD31, 1:20 dilution, DAKO) for 1 hr at room
temperature without intervening wash. Sections were then washed with phosphate
buffered saline (PBS) prior to incubation with secondary antibody (mouse
immunoglobulins, 1:50 dilution, DAKO) for 30 minutes and then mouse APAAP
(1 TOO dilution, DAKO) for 30 mins after intervening washings with PBS. The slides
were then developed in New Fuschin (DAKO), counter-stained with haematoxylin
for 1-2 mins and finally dehydrated through graded alcohols and isopropanol before
mounting in DPX.
Materials and Methods 63
CD 31 immunohistochemistry- DAB method
Tissue sections were dewaxed in xylene, rehydrated in descending concentrations of
ethanol and placed into deionised water. Antigen retrieval was achieved by
microwave heating in citrate buffer (lOOmls concentrated buffer in 900mls distilled
water) for 3x5 mins. Sections were left for 20 min in hot buffer before cooling in
water. Endogenous peroxidase activity was quenched with a 30 min incubation in 3%
hydrogen peroxide in distilled water at room temperature. To reduce non-specific
staining, sections were incubated in first avidin containing block and then biotin
block for 10 mins each incubation with an intervening wash in PBS. After a further
wash in PBS, slides were exposed to primary antibody at 4°C overnight (anti CD31
DAKO mouse anti-human, 1:20 dilution). Slides were washed three times in
phosphate buffered saline (PBS) followed by a 30 min incubation with the secondary
antibody at room temperature (DAKO rabbit anti-mouse, 1:300 dilution). For signal
amplification, the avidin-biotin complex (ABC) method was used. After incubation
with ABC horseradish peroxidase (HRP,DAKO) for 30 min at room temperature and
two washes with PBS, visualisation was achieved using diaminobenzadine DAB kit
(DAKO) with a 5 min exposure. A further wash in PBS was performed and then
counter-staining with haematoxylin for 1-2 mins was performed. Slides were then
washed with tap water and acid alcohol to remove excess haematoxylin then placed
in ammonia water to allow a blue colour to develop. Finally slides were dehydrated
through graded alcohols and xylene before mounting in DPX.
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Microvessel counts
Following immunohistochemical staining of endothelial cells as described,
microvessel counts were performed by two observers: a consultant surgeon with
previous experience and the investigator, who underwent a period of training with an
expert in the field. Counts were performed using a conference microscope.
Following scanning of the CD31 stained sections at low power (x40) microvessel
counts were performed under high power (x250) using a Chalkley eyepiece graticule
(Fox 1995). This graticule with 25 randomly allocated dots was placed in the
microscope eyepiece. Vessels were counted only if they lay under the dots. In order
to take account of the volume occupied by the vessels, those with more than one dot
overlaying them were counted more than once. Counts were performed in three high
power fields and the sum of these counts gave the microvessel count for that
specimen. Investigators performing the counts were blinded to diagnosis or timing of
sample. Statistical analysis was performed with the InStat and SPSS program version
9.0 using appropriate statistical tests for individual comparisons e.g. Mann Whitney.
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Chalkley 25 point eyepiece graticule
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CD31/MIB1 dual immunohistochemistry
Staining for MIB1 was undertaken first and the method finished as per the protocol
described above for the CD31 antibody from the stage of the primary antibody
onward. Sections were dewaxed and rehydrated through graded alcohols to distilled
water. Endogenous peroxidase activity was quenched with a 10 min incubation in 3%
hydrogen peroxide in distilled water at room temperature. Antigen retrieval was
achieved by microwave heating in citrate buffer (lOOmls concentrated buffer in
900mls distilled water) for 3x5 mins. Sections were left for 20 min in hot buffer
before cooling in water. Incubation with avidin and biotin block for 10 min each was
then undertaken with an intervening wash with TBS. DAKO protein block was
applied for a 20 min incubation and the MIB-1 primary antibody (anti MIB-1 DAKO
mouse anti-human, 1:150 dilution) applied immediately after for a 1 hour incubation
at room temperature with no intervening wash. Secondary antibody was then applied
(rabbit anti-mouse with biotin, 1:200 dilution) following washing with TBS and
incubated for 30 mins. Slides were washed in TBS before incubation for 30 mins
with the tertiary agent (Vector ABC Vectastain kit) with 3 drops applied per
chamber. Washes with TBS and distilled water were followed by application ofDAB
to each slide for 5-10 min incubation until a brown colour developed. At this point, a
further application of protein block was followed by the CD31 antibody as detailed
above.
Proliferation scores
For each section dual stained for CD31 and MIB-1 absolute numbers ofproliferating
endothelial cells were counted and totalled from three fields seen under high power
light microscopy (x250). A proliferation index (PI) was calculated for each specimen
and was expressed as;
PI = Total no. ofproliferating endothelial cells (staining pink and brown) / Total no.
ofproliferating cells (staining only brown) in same field.
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Key to figures used in descriptions of study designs
Normal kidney
Renal tumour
Renal allograft after transplantation
Materials and Methods
CAN nephrectomy specimen after excision
Cross section tissue specimen
Core biopsy tissue specimen
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1) Assessment of Vascularity in Human Parathyroid Tissue
Patient material
Having obtained ethical approval and patient consent, parathyroid tissue was
obtained from patients undergoing elective parathyroidectomy as treatment for
hyperparathyroidism either due to a parathyroid adenoma or in the setting of chronic
renal failure with four gland hyperplasia. Tissue was taken for frozen section analysis
to confirm it to be parathyroid in origin and remaining tissue made available for
study. For histopathological evaluation and in situ hybridisation, parathyroid tissues
were immediately fixed with 4% paraformaldehyde and 5pm paraffin sections were
cut. For Western blot analysis, parathyroid tissue was stored at -70° until required for
use and approximately 1 mm3 needed to extract protein lysate. Fresh tissue was
obtained from one normal gland, three separate adenomas and from three patients
with four gland hyperplasia.
Following ethical approval, formalin fixed, paraffin embedded histology blocks were
also available from patients who had undergone parathyroidectomy over the
preceding 11 years and these specimens were cut from archive specimens kept
following diagnosis. Four or five sections were obtained from each of 123
specimens.
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Study design
To determine differences in vascularity between normal human parathyroid tissue,
parathyroid hyperplasia and adenoma, histological sections from 123 patients were
obtained in this retrospective study. Following immunohistochemical staining with
antibody to CD31, microvessel counts were performed on 44 normal, 27 hyperplastic
and 52 adenomatous glands.
In addition, 91 of these sections (36 normal, 10 hyperplasia and 45 adenoma) were
immunostained with antibody to VEGF to assess for its expression and a further 15
sections (5 of each type) underwent in situ hybridisation to assess for levels ofVEGF
mRNA. Protein was extracted from 5 specimens of parathyroid tissue (1 normal, 2
hyperplasia and 2 adenoma) and Western blotting analysis performed with antibody
to VEGF.
A correlation between changes in vascularity and expression of VEGF protein and
mRNA was sought following these analyses.
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VEGF immunohistochemistry
Tissue sections were dewaxed in xylene, rehydrated in descending concentrations of
ethanol and placed into deionised water. Endogenous peroxidase activity was
quenched with a 5 min incubation in 3% hydrogen peroxide in distilled water at
room temperature. Antigen retrieval was achieved by microwave heating in citrate
buffer (lOOmls concentrated buffer in 900mls distilled water) for 3x5 mins. Sections
were left for 20 min in hot buffer before cooling in water and then washing with
TBS. Incubation with avidin and biotin block for 10 min each was undertaken with a
wash with TBS after each. A serum free protein block was applied for 5-10 mins and
not washed offprior to incubation for 2 hours at room temperature with the primary
anti-VEGF antibody (rabbit anti-human VEGF polyclonal, 1:400 dilution, sc-152
Santa Cruz Biotechnology, Santa Cruz, CA). Negative control slides were exposed to
primary antibody and VEGF blocking peptide (1:80 dilution, sc-152p Santa Cruz
Biotechnology, Santa Cruz, CA). Primary antibody was washed offwith TBS and
secondary antibody applied (goat anti-rabbit, 1:300 dilution, Santa Cruz
Biotechnology, Santa Cruz, CA) for a 30 min incubation. Slides were then washed
with TBS. For signal amplification, the avidin-biotin complex (ABC) method was
used. After incubation with ABC horseradish peroxidase (HRP, DAKO) for 30 min
at room temperature and two washes with PBS visualisation was achieved using
DAB kit (DAKO) with a 5 min exposure. Sections were washed in PBS and then
counter-stained with haematoxylin for 1-2 mins. Slides were washed with tap water
and acid alcohol to remove excess haematoxylin and placed in ammonia water to
allow a blue colour to develop. Finally slides were dehydrated through graded
alcohols and xylene before mounting in DPX. Positive control tissue from human
endometrium was used.
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VEGF assessment
Sections of parathyroid tissue stained with antibody to VEGF were scored by two
observers according to overall proportion and intensity of staining as compared to the
positive control of normal human endometrium. Assesments were made in three high
power fields (x250) and the total of three scores was documented. Intensity of
staining was compared to the positive control for each staining run. The semi¬
quantitative scoring system used was as follows:
Intensity; 0 - no staining
1 - traces of staining/mild staining
2 - moderate staining
3 - dark/strong staining
Proportion; 1 - 0 to 25% of all cells staining
2 - 25 to 50% cells staining
3-50 to 75% staining
4 - 75 to 100% staining
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In situ hybridisation to VEGF
In situ hybridisation was performed using cRNA probe for human VEGF. For each
slide a sense and anti-sense was carried out. Sense and anti-sense probes were
prepared using an RNA transcription kit (Ambion, Austin, TX) and labelled with
35S-uridine 5'-triphophate (NEN, Boston, MA). Tissue is fixed in 4% neutral
buffered formalin for 24 hours. Serial paraffin sections 5 microns thick were cut and
mounted onto BDH Super Frost Plus (cat. No. 406/0179/00) coated glass slides. The
sections were rehydrated through xylene bath followed by graded alcohols, 0.2N HC1
and then finally depc (0.1% diethyl pyrocarbonate) water. The sections were treated
with proteinase K (5pg/ml, Sigma, St. Louis, MO) for 30 min at 37°C then taken
through 0.2% glycine for 10 min at 4°C, triethanolamine buffer (TEA) for 5 min,
TEA buffer with acetic acid for 10 min and then SSC (NaCl FW 58.44, Sigma S-
3014 with tri-sodium salt FW294.1, Sigma C-8532 made to pH 7.0 with HC1 in pure
water) for 5 min. 100pl ofpre-hybridisation buffer was added to each slide and
incubated at 55°C for 2 hours. Just before use the probe was denatured at 95°C for 10
min then put on ice. Once pre-hybridisation was complete the excess buffer was
dried off and 50pl ofhybridisation buffer was added to each. Subsequent
hybridisation was performed in a moist chamber overnight at 55°C. High stringency
post-hybridisation washings and RNAase treatment were used to remove excess
probe. Slides were dehydrated and air dried for 4 hours prior to dipping in emulsion
(Ilford G5 liquid emulsion, H.A.West, Edinburgh, UK). Slides were then left in a
light proof humid box with exposure time of 7 weeks. Subsequent development of
the slides took place with Kodak D19 developer (Kodak, Rochester, NY) at 4°C and
fixed with Kodak GBS fixer Kodak, Rochester, NY) then counterstained with
haematoxylin (Richard-Allan, Richland, MI), dehydrated and mounted.
In situ hybridisation to VEGF was evidenced by the presence of clustering of silver
grains within cells seen under dark field microscopy in the anti-sense sections and
compared against a positive control ofhuman corpus luteum and negative control of
corresponding sense sections.
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Western blot analysis to VEGF
Protein extraction: Parathyroid tissue obtained from patients undergoing elective
parathyroidectomy was stored at -70°C until required. Tissue was then removed but
kept frozen in liquid nitrogen (BOC, UK) and samples no greater than 5mm in
diameter were freeze fractured using a Bio-Pulverizer Mini Dismembranator (Braun,
Germany). The resultant powder was removed and added to the protease and cell
lysis buffer and vortexed. The supernatant was removed and a protein assay
performed using the Bio-Rad protein assay kit. Final concentrations were obtained
for each tissue to allow calculation of the volume of suspended lysate required to
perform the Western blot analysis.
Western (immuno) blotting protocol; Following denaturing at 90°C for 5 mins
(Tweedle Dum) equal amounts of the lysate proteins (20pg) were loaded onto a
12.5% SDS polyacrylamide gel and separated with a 200 volt potential difference for
approximately one hour. In addition to the test samples, two additional lanes were
run, one containing known molecular weight markers for the reference range of
interest for VEGF and the other being a purified VEGF protein product (Santa-Cruz
sc-152p, Santa-Cruz Biotechnology,Ca). The proteins were then transferred to a
nitrocellulose membrane at 80mA for one hour ('Trans-Blot' transfer medium,
0.45pm, Bio-Rad, Hercules, CA)). The nitrocellulose was soaked in Ponceau red
solution (0.1% Ponceau S, 5% acetic acid, Sigma, St Louis, MO) to allow
visualisation ofprotein standards and lanes which were marked on the membrane in
pencil. Excess Ponceau red was washed offwith TBS several times before the
blocking agent is applied. A 5% TBS/skim milk powder (Marvel) solution was added
to the membrane which was blocked for one hour at room temperature. The
membrane was then removed from the blocking solution and without an intervening
wash the primary antibody was added. The primary antibody to VEGF (rabbit anti-
human, 1:1000 dilution, Santa-Cruz sc-152, Santa-Cruz Biotechnology, Ca) was
diluted in 1% bovine serum albumin (Sigma, St Louis, MO) and Marvel solution of
TBS, 0.05% Tween and incubated for one hour at room temperature. Several washes
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with TBS Tween 0.05% were performed before the secondary antibody (HRP-
conjugated goat anti-rabbit, 1:5000 dilution, Santa Cruz Biotechnology, Santa Cruz,
CA) applied for a 40 min incubation at room temperature. Two further washes with
TBS Tween 0.05% were performed followed by a final wash in TBS before the
membrane was ready for development. The signals were detected by ECL Western
blot analysis system (ECL WB Detection Reagents, Amersham Biosciences, Bucks,
UK).
Presence ofVEGF protein was detected by the presence of a protein band at the
correct molecular weight as compared to the control VEGF protein product and the
protein standards.
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2i) Validation ofmethodology - observer variation
Assessment of angiogenesis in histological sections commonly involves the use of
microvessel counts or microvessel density (Ozdemir et al 2001, Oda 2003, Kasper et
al 1999, Marson et al 2001). Tissue heterogeneity and observer variation make this
methodology susceptible to problems with reproducibility. To improve objectivity of
microvessel counts the use of a Chalkley eyepiece graticule or computerised image
analysis have been advocated (Fox et al 1995). This has been shown to generate
reproducible results thus minimising intra- and inter-observer variation (Marson et al
1999) which have previously been reported (Axelsson et al 1995).
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Patient material
For determination of intra-observer variation and inter-observer variation specimens
collected from other aspects of the study were studied. Normal kidney came from
those collected as described or from additional sections of normal kidney retrieved
from archive material following ethical approval and in collaboration with the
pathology department.
Study design
Intra- and inter observer variation were assessed. Microvessel counts were obtained
following staining of normal kidney sections with antibody to CD31. These counts
were performed on forty-five sections by observer DM at different time points and
separately by two observers DM and LM on 25 sections.
Comparison of inter-observer variation between investigators DM and LM
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Comparison of intra-observer variation between two time points for
investigator DM
Normal
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2ii) Validation ofmethodology - reproducibility study
There is recent evidence to suggest that microvascular changes contribute to certain
progressive renal diseases and that further understanding of the process of
angiogenesis may lead to novel therapeutic strategies in their treatment (Kang et al
2002, Kang et al 2003). Angiogenesis has been shown to be implicated in the
development of renal cell carcinoma (Oda et al 2003, Le Jan et al 2003, Dekel et al
2002), differing forms of glomerulonephritis (Honkanen et al, Masuda et al 2001,
Noguchi et al), glomerulosclerosis (Kang et al 2002) and renal transplant
nephropathy (Pilmore et al 1999, Ozdemir et al 2001). The use of renal biopsy tissue
in the study of renal disease provides a useful source ofmaterial for research
particularly in the study of chronic allograft nephropathy where serial specimens are
often available (Bellamy et al 2000, Freese et al 2001, Legendre et al 1998, Pilmore
et al 1999).
It is well documented that heterogeneity of vasculature is exhibited in certain human
tumours and that microvascular 'hot spots' are seen e.g. breast cancer (Weidner et al
1991, Van Hoef et al 1993). Care must be taken when interpreting microvessel
counts derived from core biopsies as they may not accurately represent the whole
tissue under study which will limit their use as a means of assessing the
microvasculature (Jacobs et al 1998). These concerns regarding accuracy of
performing microvessel counts on core biopsy specimens should not be limited
solely to the study of tumours but also to other normal and diseased tissues, although
it is often assumed that there exists homogeneity of vasculature in normal tissue.
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Patient material
Having obtained regional ethical approval and written patient consent tissue was
obtained from 27 patients undergoing elective nephrectomy, 25 for renal tumours, 1
for obstructing ureteric tumour and 1 for chronic pyelonephritis. Non-tumour tissue
was defined as 'normal' kidney and this was available from all but one of the
specimens (a partial nephrectomy where only tumour tissue was removed).
Following removal of the kidney the specimen was immediately assessed by the
pathologist and between one and three random biopsies of the normal kidney and the
tumour (where present) were performed with a disposable 14 gauge Tru-Cut biopsy
needle. Cross section specimens were then cut by the pathologist from the same area
to allow comparison with biopsies from the same kidney.
As a separate study, paired samples of tumour cross section and biopsy were also
performed, thus each specimen provided two pairs of samples (normal biopsy and
cross section and tumour biopsy and cross section per kidney).
All specimens were fixed in formalin for at least 24 hours and paraffin-embedded
following usual tissue processing through heated alcohols, xylene and wax. Sections
of 4pm were cut from each specimen to allow for immunohistochemical assessment.
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Study design
To compare results obtained from core biopsy and cross section specimens taken
from the same kidney at the same time, immunohistochemical staining was
performed with antibody to CD31.
In 27 excised kidneys, 26 core biopsy and cross section of normal kidney obtained at
the same time were available for analysis.
• Direct comparison ofmicrovessel counts between normal core biopsies and the
corresponding normal kidney sections was undertaken. Separate microvessel counts
were taken from the cortex and medulla from each section (Figure a).
• Similar direct comparison ofmicrovessel counts between tumour biopsies and
corresponding tumour cross section was undertaken (Figure b).
• Additionally direct comparison ofmicrovessel counts between cross section of
normal kidney and tumour from the same kidney was undertaken (Figure c).
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Figure a - Comparison ofMVC between cross section and core biopsy from
same kidney at same time point (Figure a
Figure b - Comparison ofMVC between cross section and core biopsy from
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Figure c - Comparison ofMVC between normal kidney and kidney tumour
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3) Changes in vascularity, endothelial cell proliferation and macrophage
infiltration in renal allograft nephrectomies with CAN compared with
normal kidney
This study compares results of normal kidney with renal allograft nephrectomy
specimens performed because of chronic allograft nephropathy. This group of
patients represents end stage CAN when graft function has failed,
immunosuppressive therapy ceased and renal replacement therapy recommenced.
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Patient material
Having obtained regional ethical approval, all pathology reports from transplant
nephrectomies performed at the Royal Infirmary ofEdinburgh between 1991 and
2002 were reviewed by a pathologist and those which showed changes of chronic
allograft nephropathy were selected for study. A total of 34 nephrectomies from 31
different patients were identified (3 patients had 2 grafts studied). Median graft
duration was 49 months (range 2 -189) with median age of recipient 45 years at time
of nephrectomy (range 30 — 69). There were 18 male and 13 female recipients from 1
living-related and 33 cadaveric donors.
Normal kidney from 62 patients was available with median age ofpatient 53 years at
time of nephrectomy (range 31 - 80). There were 37 male and 25 female patients.
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Study design
Immunohistochemical analyses were performed to compare normal kidney with the
CAN nephrectomy specimens which were:
• CD31 staining and microvessel counts
• CD31/MIB-1 dual staining and assessment of endothelial cell proliferation and
proliferation index
• CD68 staining and glomerular macrophage counts
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4) Sequential changes in vascularity, endothelial cell proliferation and
macrophage infiltration during CAN using renal allograft biopsies
This study was undertaken in two parts:
early allograft biopsy vs. endstage CAN specimen (paired samples)
protocol allograft biopsies comparing those grafts that went on to develop
CAN with those with continued stable function.
i) Renal allograft biopsy specimens obtained because of graft dysfunction in the
cohort ofpatients studied who progress to nephrectomy due to chronic allograft
nephropathy were analysed. This group ofbiopsy specimens were taken at varying
time points after transplantation but before graft failure and nephrectomy. The
specimens were compared with the cross section from the nephrectomy for each
patient and with normal kidney. This allows investigation of changes that occur
during the progression of CAN.
ii) Protocol biopsies taken early after transplantation were studied. This
population of patients contained grafts which went on to develop CAN and those in
which CAN did not develop and stable graft function ensued. This allowed for
investigation as to whether grafts which develop CAN show early changes which
may have prognostic or diagnostic importance.
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Patient material
31 transplant biopsies performed to assess the cause of deterioration in renal function
were obtained from 22 of the 34 grafts that went on to develop CAN. These are
referred to as 'clinical biopsies' in the remainder of the thesis. Biopsies were taken at
differing time points during the life of each graft (median biopsy at 17 months after
transplantation, range 1 week to 96 months). All diagnoses from these biopsies were
included for study. These were; 4 normal, 9 acute rejection, 11 CAN, 7 other.
Additionally, 28 sections from protocol biopsies were studied and MVCs obtained.
Stable graft function developed in 20 patients (median time of biopsy 20.5 days after
transplantation) and 8 developed CAN with associated deterioration in graft function
(median biopsy at 19 days).
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Study design
Three different immunohistochemical stains were applied to the clinical biopsy
group and this allowed for comparison with CAN nephrectomy tissue and normal
kidney.
• CD31 staining and microvessel counts
• CD31/MIB-1 dual staining and assessment of endothelial cell proliferation and
proliferation index
• CD68 staining and glomerular macrophage counts
Protocol biopsies were only immunostained with antibody to CD31 and microvessel
counts performed.
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Chapter 3 Parathyroid Results and Discussion
This section will detail all results obtained during experiments with parathyroid
tissue. Tables and graphs are presented for:
• significant positive results obtained with CD31 staining and microvessel counts
as well as negative results obtained from:
• VEGF immunohistochemistry,
• MIB-1/CD31 dual staining immunohistochemistry,
• YEGF in situ hybridisation and
• VEGF Western blotting
A discussion of these results then follows in this chapter with the remainder of the
thesis focussing on studies of chronic allograft nephropathy.
Parathyroid Results and Discussion
Parathyroid results
Microvessel counts
123 patients were studied (44 normal, 27 hyperplasia and 52 adenoma). Microvessel
counts were as follows:
Table 3.1: Microvessel counts
Normal Hyperplasia Adenoma







Median 13.5 26 34
Range 2-43 8-56 10-54
There was a statistically significant and step-wise increase in microvessel count
between the different types of tissue (Mann Whitney cmparison ofmeans).
Normal vs Hyperplasia: p<0.001
Normal vs Adenoma: p<0.001
Hyperplasia vs Adenoma: p=0.0027
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Figure 3.2 gives examples ofCD31 staining of normal parathyroid, hyperplasia and
adenoma with microvessel appearing brown.
Figure 3.2a. Normal parathyroid;
Less CD31 staining (x20) evident.
Figure 3.2b. Parathyroid hyperplasia;
Prominent CD31 staining (x20).
Figure 3.2c. Parathyroid adenoma;
brown CD31 staining (x20) apparent
throughout.
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Immunohistochemistry
91 sections of parathyroid tissue (36 normal, 45 adenoma and 10 hyperplasia) were
immunostained with antibody to VEGF. Intensity and proportion of cells staining
were as follows:
Table 3.2: VEGF IHC scores
Intensity Proportion
0 1 2 3 1 2 3 4
Normal 4 14 14 4 26 7 3 0
Adenoma 9 20 11 5 36 6 3 0
Hyperplasia 4 2 4 0 8 2 0 0
Table 3.3: VEGF scores - mean, median, SEM and range
Mean total score Median score Std. error of
mean (SEM)
Range
Normal 3.18 3 0.1991 0-7
Adenoma 2.39 2 0.2015 0-4
Hyperplasia 2.69 2 0.2627 ^r1o
Statistical analyses comparing mean total scores is shown below (Mann Whitney):
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Normal vs Hyperplasia: p = 0.2321
Normal vs Adenoma: p = 0.0316
Hyperplasia vs Adenoma: p = 0.6619.
58% of all sections showed either zero or mild staining (53 of 91 sections) and thus
that 42% of sections show either moderate or strong staining. Furthermore, the
degree of intensity of staining showed a similar distribution between the differing
types of tissue and there is no step-wise increase in intensity of staining between
normal, hyperplasia and adenoma as was seen with the microvessel counts.
These data also confirm that in 77% of sections (70 of 91), the proportion of cells
staining for VEGF at any intensity level is less than 25% of cells on each section.
Only 6.6% (6 of 91) of sections showed a similar proportion of cells staining (>50%
or groups 3 and 4 in the table above) to those of the positive control sections. Again
these data show no difference in the distribution of the proportion of cells staining
for VEGF between the different types of tissue.
However, taking the mean total score obtained does reveal a statistically significant
difference between normal tissue and adenoma (p=0.0316).
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Figure 3.4: Examples of IHC with antibody to VEGF
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Figure 3.4a.Positive control VEGF IHC
(immunohistochemistry) (x20), Human
endometrium; Strongly staining brown with
specificity compared to negative controls.
Figure 3.4b.Parathyroid adenoma VEGF IHC
(x20) showing less intense and less frequent
staining pattern than positive control.
Figure 3.4c.Parathyroid hyperplasia VEGF IHC
(x20) showing similar staining to adenoma and
normal tissue.
Figure 3.4d.Normal parathyroid VEGF IHC
(x20) showing staining similar to adenoma and
hyperplasia.
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CD31/MIB-1 Dual Stain
133 sections were dual stained with antibodies to CD31 and MIB-1 (which stains the
nuclear protein Ki-67, a marker of cells undergoing proliferation) as described above.
Endothelial cells were visualised under a light microscope by a characteristic reddish
pink colour as determined by the staining method used to detect CD31. MIB-1
positive cells were identified by a characteristic dark brown staining of the nucleus.
Proliferating endothelial cells were thus identified as those with both red and brown
staining. Three high power fields (x250) were selected at random and cell counts
performed for the total number of proliferating cells per field as well as the total
number of proliferating endothelial cells. After analysis of 57 sections:
• the maximum number ofproliferating endothelial cells in any given field was 1
• these cell types were only seen in 14% (8 of 57) of the sections studied
• 29 sections (51%) showed no proliferating cells of any kind.
• proliferating endothelial cells were visualised in both normal and adenoma sections
(but not hyperplasia) but not in significantly differing numbers.
Scanning of the remaining 77 sections demonstrated a similarly low number of
proliferating cells and formal counting was not performed. These findings do not
offer an explanation to the significant increase in microvessel counts seen in
hyperplasia and adenoma as detailed above. It might have been expected that the
increase in microvessel count was associated with a significant increase in the
number of proliferating endothelial cells.
Consultation with a senior consultant pathologist revealed that owing to the
morphology of small blood vessels and the thickness of sections cut that
identification ofproliferating endothelial cells would probably require analysis of
serial sections from each patient. With the exception ofparathyroid samples
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collected prospectively form the start of the study such sections were not available
for analysis. This therefore is an area of further study.
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In Situ Hybridisation
Sense and anti-sense sections of parathyroid tissue from 5 normal, 5 hyperplasia and
5 adenoma were available for study. Exposure occurred at 11 weeks with trial
sections developed at the 3 and 6 week stage. Sections were counterstained with
haematoxylin and viewed under light and dark field microscopy to identify clustering






Clustering present - antisense Yes No No No
Clustering present - sense No No No No
Clustering was absent in all sense sections studied as expected for negative control.
Clustering was present in all antisense sections of positive control corpus luteum
developed after a 6 week exposure as per normal protocol for this tissue. Tests slides
of each type ofparathyroid tissue were studied at 3 and 6 weeks and no clustering
was present. The study sections were left for an 11 week exposure prior to
development. Again these sections showed no evidence of hybridisation to VEGF in
any type ofparathyroid tissue.
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Western blotting analysis
The protein lysate from parathyroid tissue form 1 normal gland, 3 adeonomas and 4
hyperplastic glands (from the same patient) were studied. The presence or absence of
a band of protein at the same latitude as the positive control purified VEGF product
(approx. 46 kDa) was used as the criterion for whether each type of tissue expressed
VEGF in vivo at the time of specimen collection. Results with first antibody trialled
(Santa-Cruz polyclonal rabbit anti-human) showed that no tissue type expressed
VEGF and also that the purified VEGF product itself showed more than one distinct
band at 46 kDa as expected. Further work with a monoclonal antibody to VEGF was
unable to produce any bands even in the channel with purified VEGF protein product
despite extensive efforts to optimise the methodology.
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Discussion
The treatment of secondary hyperparathyroidism has been the subject of surgical
debate since the description by Wells in 1975 of a technique involving total
parathyroidectomy with re-implantation into forearm muscle. Studies have been
undertaken to ascertain whether this method is preferable to sub-total
parathyroidectomy (Wells et al 1975, Takagi et al 1984) where part of one
parathyroid is left in situ in the patients' neck. Central to any discussion over the
merits of autotransplantation is the assessment of graft function or 'take' (Saxe 1984,
Brown et al 1979, Wells et al 1977) either from tissue removed and re-implanted at
the time of surgery or cryopreserved parathyroid tissue (Brennan et al 1979). Thus
far, no consistent system exists which clearly defines outcome in this field but
common outcome measures include restoration of normocalcaemia, resolution of
symptoms and no further requirement for surgery for recurrent disease (Baumann et
al 1993).
Successful survival ofparathyroid tissue following implantation into forearm muscle
must be dependent on the development of a new blood supply from the existing
microvasculature of the muscle bed to which it is grafted i.e. angiogenesis must be
stimulated by the parathyroid gland itself in vivo. When trying to mimic parathyroid
transplantation in vivo, a robust angiogenic response has been demonstrated by tissue
derived from human samples with a histological diagnosis of hyperplasia and
adenoma (Saxe 1984). This was later replicated with normal canine parathyroid
tissue using an in vitro model of angiogenesis (Carter et al 1996) and then again with
normal human parathyroid tissue in vitro (Carter et al 2000). Having established the
presence of new blood vessel formation stimulated by parathyroid tissue in vitro,
research now concentrates on the role of known mediators of angiogenesis.
It has been shown, in the same model of angiogenesis, that following explant there is
a twelve fold increase in the expression of vascular endothelial growth factor
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(VEGF) mRNA as shown by quantitative reverse transcription polymerase chain
reaction analysis in human parathyroid cells and furthermore that the angiogenesis
stimulated by this tissue is completely obliterated by the coculture with FLT-1
soluble fusion protein (Carter et al 2000). This work strongly implicates VEGF as
being an important mediator of parathyroid-induced angiogenesis in this model and it
has further been shown that angiopoietin-2 modulates this response (Carter et al
2001). The relevance of understanding how a parathyroid gland can survive explant
and autotransplantation using an in vitro model pertains to its use in developing
strategies to improve graft function following surgery. The suggestion of this work is
that transplantation could take place in a favourable milieu by the systemic or local
application of a 'pro-angiogenic' substance which will lead to improved outcome.
The data presented in this thesis do not directly address the subject of how human
parathyroid tissue stimulates angiogenesis when transplanted but rather examines the
difference in the microvasculature (and thus angiogenesis) between parathyroid
tissue ofdiffering histological type - namely normal, hyperplasia and adenoma.
Evidence is presented which shows angiogenesis occurs early in the development of
parathyroid disease but which is not associated with a significant increase in the
number ofproliferating endothelial cells, a finding which is likely to be due to
technical considerations. Furthermore, using a triad ofmethodologies
(immunohistochemistry, in situ hybridisation and Western blot analysis) to look for
the expression ofVEGF protein or mRNA in human parathyroid tissue, no
significant increase between the differing types of tissue were observed. Indeed a
counter intuitive result was obtained showing mean total VEGF
immunohistochemistry scores to be higher in normal tissue than in adenoma. This
suggests that in vivo, VEGF does not play a significant role in the regulation of
angiogenesis in the setting of parathyroid disease.
A recent similar study has also demonstrated higher microvessel density (MVD) in
parathyroid adenoma and hyperplasia versus normal gland although did not
demonstrate the same step-wise progression presented here (Garcia dela Torre et al
2004). This increase in MVD correlated with an increased expression of fibroblast
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growth factor 2 (FGF-2) but not with VEGF. Hence our data are supported by
another study but do not concur with previous published data and it should be borne
in mind that those who have demonstrated parathyroid induced angiogenesis to be
VEGF dependent were using parathyroid cell culture and an in vitro assay and
looking at the early response to transplantation. Furthermore it is not known whether
other endocrine tissue may respond in the same way to the experimental conditions
that the parathyroid cells were exposed to.
It could be postulated therefore that increased expression ofVEGF may have a role
in promoting angiogenesis in vivo but that this response is not sustained and must be
continued by other mediators of angiogenesis. This is an area which will merit
further investigation and may be best studied in parathyroid tissue that has been
implanted and functioning.
Although it has been demonstrated that parathyroid proliferative lesions demonstrate
evidence of angiogenesis it is likely that this progression to an angiogenic phenotype
occurs through differing pathways. This is evidenced in part by the discovery that
genes up-regulated in parathyroid adenoma are those responsible for angiogenesis
and production of blood vessels whereas genes down-regulated in adenoma but
expressed in parathyroid hyperplasia are related to a decrease in apoptosis (Schachter
et al 2002). This study concluded that the two are different physiologic conditions
and that further analysis of kinase genes involved in angiogenesis and apoptosis will
enable targeting of the key genes responsible for the development of hyperplasia and
adenoma.
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Chapter 4: Validation studies - assessment of observer
variation and reproducibility of microvessel counts in renal
biopsy specimens
This section presents the results of the experiments described in sections 2i and 2ii in
the Materials and Methods chapter which were:
• assessment of observer variation by comparison ofmicrovessel counts in normal
kidney between two observers and at two time points by one observer (section 2i).
• comparison ofmicrovessel counts between core biopsy and cross section pairs from
normal kidney (section 2ii),
• comparison ofmicrovessel counts between core biopsy and cross section pairs from
kidney tumour
• comparison of microvessel counts between cross sections and biopsies from normal
kidney and tumour from the same patient
The first two experiments are of direct relevance to the later studies described below.
Reproducibility ofmicrovessel counts by the principal investigator must be
demonstrated in order for that technique to be confidently employed in later
experiments comparing MVCs between normal and CAN kidney (chapter 5).
Validation of the use of MVCs in renal biopsy specimens as being representative of
MVCs in kidney cross section specimens is necessary in order to use renal allograft
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specimens in the study of the progression of vascular changes during CAN (chapter
6+7).
The study ofMVCs in renal tumour specimens is of less direct relevance to further
studies presented here. These data are included for two reasons:
they provide confirmation that normal kidney microvasculature studied from
kidneys with coexisting tumours and used as control is unaffected by the
adjacent tumour




Inter-observer and sampling variation
Microvessel counts were performed separately by two observers (mvcDM and
mvcLM) to assess inter-observer variation (Figure 4.1). Counts were performed with
a conference microscope with each observer looking at the same fields from the same
section at the same time and recording scores. These were then compared once all
counts had been performed.A significant correlation was found between the counts
of the two observers (Pearson correlation: cortex r=0.8844 with p<0.0001, medulla
r=0.98 with p<0.0001).
Microvessel counts were performed by observer DM at two separate time points one
month apart (mvcDM 1 and mvcDM2) to assess for sampling variation and intra-
observer variation (Figure 4.2). The counts were obtained from the same sections but
in differing fields each time. Thus variation in counts may occur either due to a
change in technique by observer DM or by virtue of examining different fields within
each section. However a significant correlation was found between the two counts
from observer DM which demonstrates that the method is not susceptible to
sampling variation or intra-observer variation (Pearson correlation: cortex r=0.68
with pO.OOOl, medulla r=0.61 with p=0.0002).
Pictures ofCD31 staining of normal kidney cortex and medulla will be presented in
the next chapter.
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Figure 4.1 - Inter-observer variation: LM vs. DM
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Cortical staining, r=0.8844 with p<0.0001. (Pearson correlation)
Medullary staining, r=0.98 with pO.OOOl (Pearson correlation)
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Figure 4.2 - Sampling and intra-observer variation: DM1 vs. DM2





















Intra-observer variation - medulla
Cortical staining, r=0.68 with p<0.0001. (Pearson correlation)
Medullary staining, r=0.61 with p=0.0002 (Pearson correlation)
Validation studies
Comparison of microvessel counts between core biopsy and cross section pairs
from normal kidney
Microvessel counts were performed on 25 of the 26 specimens of normal kidney and
kidney biopsy. One specimen did not stain for CD31 and was therefore unsuitable for
analysis. Due to variations in specimen collection not all 25 samples provided both
cortical and medullary results. 20 pairs of cortical counts and 17 pairs ofmedullary
counts were obtained and all biopsy specimens included in the analysis of cortical
counts had greater than 7 glomeruli, defined as adequate using Banff classification
(Racusen 1997).
Cortical and medullary MVCs for the paired cross-section (xs) and biopsy (bx)
demonstrate a highly significant positive correlation (cortical counts, r=0.7658,
pO.OOOl; medullary counts, r=0.8429, p<0.0001)(Figure 4.3).
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Figure 4.3 - Correlation between Normal Biopsy MVC and Cross Section MVC
(same kidney)
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Cortical staining, r=0.7658 with p<0.0001. (Pearson correlation)
Medullary staining, r=0.8429 with p<0.0001. (Pearson correlation)
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Microvessel counts were performed on all of the 26 specimens of kidney tumour and
biopsy. Several specimens did not stain for CD31 and were therefore unsuitable for
analysis. Due to variations in specimen collection not all 26 samples provided
results. 20 cross section counts and 20 biopsy counts were obtained and all biopsy
specimens included in the analysis of cortical counts had greater than 7 glomeruli,
defined as adequate using Banff classification (Racusen 1997).
Heterogeneity of vasculature is exhibited in certain human tumours and
microvascular 'hot spots' are seen e.g. breast cancer (Weidner et al 1991, Van Hoef
et al 1993). If such heterogeneity existed in renal cell carcinoma then it would be
anticipated that core biopsy specimens may 'miss' these hot spots and give lower
microvessel counts than the corresponding tumour cross section.
The architecture of tumour sections and vascularity was distorted compared to
normal kidney as shown above in Figure 4.4.
Figure 4.5 shows MVCs for the paired tumour cross-section (xs) and biopsy (bx)
demonstrating a highly significant positive correlation (counts, r=0.7450, p=0.0002).
This interesting observation implies that there exists a homogeneity of
microvasculature in the renal tumours studied here.
Validation studies 116
Figure 4.4: Comparison of CD31 staining in normal kidney vs. renal tumour
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Renal tumour with no glomeruli visible and marked CD31 immunostaining.
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Figure 4.5 - Correlation between Tumour Biopsy MVC and Tumour Cross
Section MVC (same kidney)
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Tumour staining, r=0.7450 with p = 0.0002. (Pearson correlation)
Validation studies
Comparison of microvessel counts between cross sections and biopsies of
normal kidney and tumour from the same patient
Microvessel counts were performed on 25 of the 26 specimens of normal kidney and
all 26 specimens of tumour. Several specimens did not stain for CD31 and were
therefore unsuitable for analysis. Due to variations in specimen collection not all 25
samples provided results. 20 cross section counts and 17 biopsy counts were
obtained.
Table 4.1 -MVC In normal kidney and renal tumour
Cross section Biopsy
Normal cortex 22.0 (12-31) 4.95 20.9 (11-28) 3.96
Normal medulla 20.1 (13-30) 4.02 20.8 (15-27) 3.57
Tumour 26.9 (20-40) 5.80 26.1 (15-38) 5.56
Mean (Range) Standard deviation
Tumour vs. normal cortex: p = 0.0040 (Paired t-test)
Tumour vs. normal medulla: p<0.0001 (Paired t-test)
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Figure 4.6 - Correlation between Tumour MVC and Normal Kidney MVC
(same kidney)
Tumour vs Normal
Mean and Standard Error
A B
Column
A - Tumour MVC
B - Normal MVC
There is significant increase in tumour MVC (26%) compared with the surrounding
normal kidney. Comparing mean tumour MVC with mean normal (cortex and
medulla combined) MVC p = 0.0347.
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Discussion
The present study has attempted to assess the variation in assessment of angiogenesis
in kidney sections which might be caused by lack of reproducibility ofmethodology
or heterogeneity of tissue.
Tissue heterogeneity of microvasculature was investigated in the present study by
comparing microvessel counts in renal core biopsies and cross-sections taken
simultaneously. Counts were performed for both the cortex and medulla of each
section and a statistically significant correlation between the two counts was
achieved. This supports the use of microvessel counts in renal biopsy material in the
assessment of angiogenesis as being representative of the kidney as a whole and
further suggests that there exists a homogeneity of vasculature in the kidneys studied
here and that the phenomenon of vascular 'hot spots' is not present in this tissue as
has been shown in human tumours (Weidner et al 1991, Van Hoef et al 1993). The
wider implication of these results is that they will allow for the use ofmicrovessel
counts from renal biopsy specimens where this offers the only available source of
tissue to study and to draw inference about the kidney from which the biopsy was
taken.
There was a highly significant correlation between counts performed by two different
observers and between two time points for one observer. Previous studies that have
addressed the issue of observer variation when performing microvessel counts have
advocated the use of a period of training with an experienced observer (Vermeulen et
al 1997), the use of a Chalkley eyepiece graticule (Fox et al 1995, Marson et al 1999)
and the use of a conference microscope (Hansen et al 1998). All of these factors have
been included in this present study to minimise observer variability and our results
are comparable with those published (Vermeulen et al 1997, Fox et al 1995, Marson
et al 1999).
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This present study has employed an artificial technique of specimen collection in
order to acquire sufficient samples of paired biopsies and cross sections taken
simultaneously from the same kidney. The authors accept that this method only
mimics that seen in clinical practice where the percutaneous collection of renal
biopsy material is performed.
Furthermore, some of the kidney which has been studied has been taken from organs
in which a renal tumour co-exists which may have the effect of distorting the
'normal' kidney vasculature however sections were confirmed by a pathologist to be
normal kidney. Microvessel counts were also performed on specimens of tumour
taken simultaneously with the normal kidney and shown to be significantly higher
(26% increase in MVC, p=0.0347) suggesting that although the tumour vasculature
has expanded this effect is not experienced by the surrounding non-tumour kidney.
In summary, accepting the limitations of the study design as dictated by the
constraints of the source of tissue used, this study addressed the validity of using
microvessel counts from renal biopsies to represent the kidney as a whole and also
the practical issues regarding this methodology. Observer variation of counts was
similar to the results of other studies in other tissues as a result of the use of
experienced observers, a Chalkley eyepiece graticule and a conference microscope.
Homogeneity of kidney microvasculature has been demonstrated using this
reproducible method which will allow future investigators to use biopsy as a more
readily available source of renal tissue in the investigation angiogenesis in renal
disease. These data have also allowed quantification of the expansion of
microvasculature that occurs in renal tumours.
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Chapter 5: Changes in vascularity in allograft nephrectomy
specimens with chronic allograft nephropathy
In the previous chapter it was demonstrated that immunostaining of renal tissue with
antibody to CD31 followed by performing microvessel counts (MVCs) was a
reproducible methodology in experienced hands and with the appropriate technique.
Having validated the use of this methodology it was possible to perform MVCs on
nephrectomy specimens performed because of chronic allograft nephropathy (CAN)
and compare these with normal kidney.
As will be presented below, there was a significantly lower MVC in the CAN group
suggesting loss ofmicrovasculature during the development ofCAN. Further
investigation was undertaken to seek an association of this finding with endothelial
cell proliferation and macrophage infiltration within the allografts.
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Results
This section presents results obtained using three immunohistochemical staining
methods to compare normal kidney with nephrectomies performed because ofCAN.
Examples of each staining method are presented on the next pages.
• Figure 5.1 shows representative samples of the immunohistochemical analysis of
normal renal tissue stained with the CD31 antibody.
• Figure 5.2 shows cortical and medullary sections from normal and CAN kidney
stained with antibody to CD31.
• Figure 5.3 shows an example of dual CD31/MIB-1 staining with a proliferating
endothelial cell marked. This image is from parathyroid tissue as this most clearly
demonstrates the appearance of a proliferating endothelial cell also seen in the
kidney specimens.
• Figure 5.4 shows an example ofCD68 staining with a glomerular macrophage
marked.
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Figure 5.1; Normal kidney CD31 staining cortex and medulla
Normal cortex (above) showing three normal glomeruli and a prominent vessel in the
top right corner.
Normal medulla (above) showing healthy tubules and normal regular vasa recta
staining pink.
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Figure 5.2 - CD31 staining of CAN nephrectomy
Cortex of nephrectomy with CAN. There is loss of normal architecture within the
glomeruli and a reduction in CD31 staining compared with the normal cortex.
Medulla of nephrectomy with CAN. There is tubular loss, some fibrosis and marked
loss of vasa recta compared with normal.
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Figure 5.3 - Example of proliferating endothelial cell
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The dual stained (brown and pink) proliferating endothelial cell is marked at the top
right of the image. This image is taken from parathyroid adenoma and demonstrates
two main vessels to the left and right of the image (pink staining) and evidence of
cellular proliferation (brown staining cells seen throughout the image).
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Two glomerular macrophages (brown) are present in the centre of the image.
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Comparison between MVC of normal kidney and CAN nephrectomy
There was a loss of regularity ofCD31 staining in CAN nephrectomies compared
with normal (Figure 5.2). Due to variations in intensity of staining, tissue availability
and small specimen size, not all samples provided both cortical and medullary
results. Cortical microvessel counts were obtained from 29 nephrectomies performed
because ofCAN and 61 specimens of normal kidney. Medullary microvessel counts
were obtained from 28 CAN nephrectomies and 45 specimens of normal kidney.
Table 5.1 and Figure 5.5 show a significant reduction in MVC in the CAN
nephrectomy group compared with normal kidney (p<0.0001 and p<0.0001 for
cortex and medulla respectively).
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Mean 22.36 15.08 21.31 15.15
Standard
deviation (SD)




0.45 0.44 0.48 0.50
Range 12-32 11-22 13-30 11-23
Cortex:Mean MVC Normal vs CAN: p<0.0001 (Paired t-test)
Medulla: Mean MVC Normal vs CAN: p<0.0001 (Paired t-test)
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Figure 5.5 - Mean MVC CAN Nephrectomy vs. Normal Kidney
MVC: CAN vs Normal Cortex
Mean and Standard Error
A B
Column
MVC: CAN vs Normal Medulla
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Comparison between no. of proliferating endothelial cells in normal kidney and
CAN nephrectomy
Following dual staining with CD31 and MIB-1, scores were obtained from 18 CAN
nephrectomies and 11 normal kidneys and results presented below (Table 5.2 and
Figure 5.6).
A significantly higher number of proliferating endothelial cells were present in the
CAN nephrectomy group versus normal (p<0.0001).
The proliferation index in the CAN nephrectomy group was significantly higher than
in normal kidney (p<0.0001).
Thus, despite a significantly lower MVC, the CAN group have a significantly higher
number of proliferating endothelial cells compared to normal kidney.
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Table 5.2 - Number of Proliferating Endothelial Cells (PECs) and Proliferation
Index (PI) in Normal kidney vs. CAN Nephrectomy
Normal PEC CAN PEC Normal PI CAN PI
Mean 0.44 5.05 0.03 0.19
Standard
deviation (SD)




0.16 0.74 0.011 0.016
Range 0-2 1 - 15 0-0.12 0.07-0.30
Normal vs. CAN: p<0.0001 for mean no. of proliferating ECs (Student t-test)
Normal vs. CAN : pO.OOOl for mean PI (Student t-test)
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Figure 5.6 - Number of Proliferating Endothelial Cells (ECs) and Proliferation
Index (PI) in Normal kidney vs. CAN Nephrectomy
PEC: CAN vs Normal







PI: CAN vs Normal
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Comparison between number of glomerular macrophages in normal kidney and
CAN nephrectomy
Following staining with the antibody to CD68, the number of glomerular
macrophages were counted in several high power (x250) fields. Where possible 20
glomeruli were counted for each section studied.
Sections from 18 normal kidneys and 29 nephrectomies performed because ofCAN
were studied.
The glomerular macrophage index (GMI) was calculated as;
GMI = Total no. of glomerular macrophages / No. of glomeruli studied per section
Table 5.3 and Figure 5.7 show that despite a trend for CAN nephrectomies to have a
higher GMI this was not statistically significant.
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Table 5.3 - Comparison of GMI in Normal Kidney and CAN Nephrectomy










Mean GMI: Normal vs. CAN: p = 0.0368 (Unpaired t-test). There is a significantly
higher GMI in samples ofCAN nephrectomy specimens than normal kidney.
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Figure 5.7 - Comparison ofmean GMI between normal kidney and CAN
nephrectomy
GMI: CAN vs Normal
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Discussion
These results show that end stage CAN is associated with significant loss of
microvasculature as shown by the reduced microvessel count in this group. This loss
of microvessels has occurred despite evidence ongoing attempts at endothelial repair
as demonstrated by the presence of proliferating endothelial cells in the CAN group.
An explanation for these findings is that despite the presence of end stage CAN there
remains a stimulus within the graft to repair endothelial cells and restore normal
vasculature i.e. angiogenesis. Further studies of levels of expression of known
mediators of angiogenesis (e.g. VEGF) in this tissue may confirm that this is the
case.
There was a statistical significant increase in numbers of glomerular macrophages in
CAN compared with normal. The relevance of this finding is uncertain as cessation
of immunosuppressive therapy in the CAN group is likely to be associated with an
increase in macrophage number. Alternatively the higher number ofmacrophages
may represent a cause for microvessel loss via macrophage mediated endothelial cell
killing.
These findings support a hypothesis that early following transplantation there is
stimulation of angiogenesis but that with progression ofCAN, microvessel loss
predominates. Evidence that persistent attempts at tissue repair (manifested by the
presence of proliferating endothelial cells) are ongoing even with end stage disease
may be of great clinical relevance and could provide an area for novel therapeutic
intervention.
The following section of this thesis examines these changes in vasculature and
endothelial cell proliferation by studying biopsies from the grafts studied in this
section which developed CAN.
Studies that were beyond the scope of this thesis which would be of future interest
include:
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• assessment of the expression of specific mediators of angiogenesis during
development ofCAN and the correlation with MVC
• a dynamic assessment of endothelial cell proliferation and death and a correlation
with both MVC and the expression of specific mediators of angiogenesis.
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Chapter 6: Changes in vascularity associated with chronic
allograft nephropathy using allograft biopsies
Results from the previous chapter demonstrated a significant reduction in
microvessel count (MVC) in end stage CAN to be associated with a significantly
higher number of proliferating endothelial cells when compared with normal kidney.
A possible hypothesis to explain this finding is that angiogenesis is stimulated
following transplantation but that with progression ofCAN microvessels are lost
despite attempts at repair.
In order to examine this finding further, biopsy specimens from some of the
allografts that developed CAN were studied and similar immunohistochemical
analyses performed.
The validity of measuring MVCs in kidney biopsies to assess vascularity of the
kidney as a whole has been confirmed and results presented in Chapter 4.
The biopsy specimens were taken because of clinical indication at a variable time
after transplantation - mean 24 months, median 17 months after transplantation - and
at a variable time prior to nephrectomy (details included in Materials and Methods
section). At the time of biopsy all allografts had some degree of function and all
patients were receiving calcineurin inhibitor immunosuppressive therapy.
By comparing each biopsy with the paired nephrectomy specimen it was possible to
assess earlier changes in vascularity that occur during the progression ofCAN which
would give an indication as to the dynamic changes that occur.
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Results
Comparison between MVC of CAN nephrectomy and clinical biopsy
Due to variations in intensity of staining, tissue availability and small specimen size,
not all of these samples provided both cortical and medullary results.
Microvessel counts were first compared between normal kidney and clinic biopsies
to assess earlier changes in the microvasculature. These were unpaired samples. A
paired comparison was then made between biopsy and nephrectomy specimens from
the same graft. As previously these data are presented for cortex and medulla.
A significant reduction in cortical and medullary MVC was seen comparing normal
kidney with the biopsy specimens from kidneys that went on to develop CAN (Table
6.1 and Figure 6.1).
As detailed in Table 6.2 and Figure 6.2, a significant reduction in MVC was shown
in the CAN nephrectomy group compared with the antecedent/clinical biopsies.
These data confirm that early in the development ofCAN there is some preservation
ofmicrovasculature with significantly higher numbers ofmicrovessel present in the
biopsy group. Again an association of this finding with endothelial cell proliferation
and macrophage infiltration has been sought.
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Mean 22.36 19.00 21.31 18.34
Standard
deviation (SD)




0.45 0.35 0.48 0.54
Range 12-32 13-23 13-30 12-25
Mean cortical MVC: Normal vs. CAN Bx: p<0.001 (unpaired t-test)
Mean medullary MVC: Normal vs. CAN Bx: p<0.001 (unpaired t-test)
There is a significant reduction in MVC in the biopsy specimens taken from grafts
which develop CAN.
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Figure 6.1 - Mean MVC Normal Kidney vs AH CAN Bx (Cortex and Medulla)
MVC: Normal vs All CAN Bx - Cortex








MVC: Normal vs All CAN Bx - Medulla









B - CAN Bx
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Mean 19.00 15.18 18.34 15.28
Standard
deviation (SD)




0.35 0.42 0.54 0.49
Range 13-23 12-18 12-25 11-19
Cortical MVC: Paired CAN Bx vs CAN XS: pO.OOOl (Paired t-test)
Medullary MVC: Paired CAN Bx vs CAN XS: p=0.0002 (Paired t-test)
MVC in biopsy specimens from grafts which develop CAN are significantly higher
when compared with the MVC from the same nephrectomy specimen.
Microvessel counts in clinical biopsies 143
Figure 6.2 - Mean MVC Paired Clinical Biopsy vs. CAN nephrectomy (cortex
and medulla)
Paired MVC: CAN Bx vs XS - Cortex
Mean and Standard Error
A B
Column
Paired MVC: CAN Bx vs XS - Medulla
Mean and Standard Error
A B
Column
A - CAN Bx
B-CAN XS
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Comparison between number of proliferating endothelial cells in CAN
nephrectomy and clinical biopsy
Following dual staining with CD31 and MIB-1, scores were obtained from 18 CAN
nephrectomies, 14 biopsies and 11 normal kidneys.
Table 6.3 and Figure 6.3 demonstrate that a significantly higher number of
proliferating endothelial cells were present between the biopsy group and normal
(p<0.0001). This is relevant in that it confirms that earlier in the development of
CAN there are ongoing attempts at tissue repair.
Comparison between the biopsy specimens and the nephrectomies was performed to
determine whether there was a significant difference in the degree of endothelial cell
proliferation at different time points in CAN. Table 6.4 and Figure 6.4 confirm that
there is no significant difference in the number of proliferating endothelial cells was
observed between the nephrectomy and biopsy groups (p=0.471 - paired t-test).
These data demonstrate that proliferating endothelial cells are present in allograft
biopsy specimens early in the development ofCAN and at levels greater than seen in
normal kidney.
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Table 6.3 - Number of Proliferating Endothelial Cells (PECs): Normal kidney














Mean PEC: Normal vs CAN Bx: p<0.001 (Unpaired t-test).
There is a significantly higher number of proliferating endothelial cells in CAN
biopsy specimens when compared with normal kidney.
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Figure 6.3 - Mean no. of proliferating endothelial cells Normal vs. CAN biopsy
PEC: Normal vs CAN Bx




B - CAN Bx
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Table 6.4 - Number of Proliferating Endothelial Cells (PECs): Biopsy (Bx) from













Range 2-8 1 - 15
Mean PEC: CAN Bx vs CAN XS: p=0.471 (Unpaired t-test).
There is no significant difference in the number of proliferating endothelial cells in
CAN biopsy specimens when compared with the paired CAN nephrectomy
specimen.
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Figure 6.4 - Mean no. of proliferating endothelial cells CAN biopsy vs. CAN
Nephrectomy
PEC: CAN Bx vs CAN XS
Mean and Standard Error
A B
Column
A - CAN Bx
B - CAN XS
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Comparison between number of glomerular macrophages in CAN nephrectomy
and clinical biopsies
Following staining with the antibody to CD68, the number of glomerular
macrophages were counted in several high power (x250) fields. Where possible 20
glomeruli were counted for each section studied.
Sections from 18 clinical biopsies and 29 nephrectomies performed because ofCAN
were studied as described above. Sections of normal kidney were also studied.
A glomerular macrophage index (GMI) was calculated as;
GMI = Total no. of glomerular macrophages / No. of glomeruli studied per section
Table 6.5 and Figure 6.5 show that CAN nephrectomies have a statistically
significant higher GMI than normal kidney.
Howevr, Table 6.6 and Figure 6.6 show that there is a significantly lower GMI in the
clinical biopsy specimens when compared with the nephrectomies.
These data do not support or refute a hypothesis that macrophage infiltration is a
significant factor in the development of CAN or loss of microvasculature
demonstrated in this thesis. As has been mentioned earlier and will be discussed
later, there are other factors such as cessation of immunosuppressive therapy that
must be taken into account when interpreting these data.
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Mean GMI: Normal vs CAN nephrectomy: p=0.0368 (unpaired t-test).
There is a significantly higher glomerular macrophage index in CAN nephrectomy
specimens when compared with normal kidney.
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Figure 6.5 - Mean GMI comparing Normal kidney and CAN nephrectomy
GMI: Normal vs CAN Nephrectomy
Mean and Standard Error
Column
A - Normal
B - CAN Nephrectomy
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Table 6.6 - Comparison ofGMI between CAN Biopsy and CAN Nephrectomy










Mean GMI: CAN Biopsy vs CAN nephrectomy: p<0.0001 (paired t-test).
There is a significantly higher glomerular macrophage index in CAN nephrectomy
specimens when compared with the paired antecedent biopsy.
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Figure 6.6 - Mean GMI comparing CAN Biopsy with CAN nephrectomy
GMI: CAN Biopsy vs CAN Nephrectomy
Mean and Standard Error
Column
A - CAN Bx
B - CAN Nephrectomy
Microvessel counts in clinical biopsies 154
Discussion
Comparison of clinical biopsy with paired nephrectomy specimens has demonstrated
the following results:
• MVC is significantly higher in the earlier biopsy specimens but less than that seen
in normal kidneys
• proliferating endothelial cells are present in similar numbers throughout the
progression ofCAN but in significantly higher numbers than in normal kidney
• the number of glomerular macrophages falls in the earlier stages of CAN but then
significantly rises as CAN progresses
These data provide further insight into the dynamic process occurring in the
vasculature early in the development ofCAN and continue to support a hypothesis
that angiogenesis is stimulated early following transplantation.
The limitations of this study relate to the tissue used. Nephrectomy specimens were
obtained following cessation of immunosuppression which may affect both
angiogenesis and macrophage infiltration. The biopsies were performed due to
clinical indication e.g. a rise in serum creatinine and the presence of acute rejection
or viral infection may be a stimulus for endothelial cell proliferation.
There are two strategies that may be employed to overcome these problems.
i) As described in the Introduction chapter, development of animals ofCAN
would allow for acquisition of tissue at regular intervals during
progression ofCAN and in a murine model allow knockout experiments
to be conducted e.g. macrophage deplete recipient mice.
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ii) The use of protocol biopsy specimens from human allografts.
The former strategy is being developed within our research group but with no tissue
yet available for study.
The latter strategy relies on clinicians performing protocol biopsies and this has not
been the practice at the Transplant Unit in Edinburgh.
However, following collaboration with the Oxford Transplant Centre where protocol
biopsies are performed at day 7 and 28 following transplantation, the following
chapter will detail results obtained comparing MVCs in early protocol biopsies.
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Chapter 7: Microvessel counts using protocol renal allograft
biopsy specimens
Previous results presented have demonstrated that during the progression ofCAN
there are ongoing attempts at tissue repair as manifested by the presence of
proliferating endothelial cells.
Furthermore it has been shown by the use of clinical biopsy specimens that in the
earlier stages ofCAN there is some preservation ofmicrovasculature compared with
end stage disease although there is already evidence of significant microvessel loss in
these specimens. However the median timing of these clinical biopsies was 17
months after transplantation (range 1 week to 96 months) and thus unable to provide
robust data to examine changes in microvasculature in the first few days and weeks
following transplantation.
It is during the initial post-transplant phase that the allograft is subjected to various
insults such as:
• host immune response
• ischaemia-reperfusion injury
• nephrotoxic drugs
Processes that occur during this phase may not be immediately manifested clinically
and thus clinical biopsies performed because of signs of graft deterioration may not
accurately reflect the cellular changes that have occurred.
Debate exists about the merits of performing protocol biopsies and not all clinicians
or transplant centres advocate their use. The risks of damaging the transplanted
kidney or causing significant morbidity to the patient must be balanced with the
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possible benefits of detecting sub-clinical disease. An additional benefit
performing protocol biopsies is to the researcher.
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Results
Protocol biopsy specimens from renal transplants were obtained from the Oxford
Transplant Centre following ethical approval and written patient consent. Samples
were obtained between 1985 and 1996. Follow-up of graft function ranged from 8 to
19 years.
A total of 30 biopsies were studied following immunostaining with antibody to
CD31 as described above. Microvessel counts (MVCs) were performed with the
investigator blinded to graft outcome.
The 30 patients were then divided into two groups according to graft outcome:
20 patients experienced stable graft function
10 patients developed CAN (confirmed by later clinical biopsy).
Due to restrictions of specimen availability it was not possible to compare MVC in
early protocol versus later clinical biopsy in the group where CAN developed.
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Timing of protocol biopsies was similar in each group as shown in Table 7.1:
Table 7.1 - Timing of protocol biopsy
Timing of biopsy (day)
Stable graft 19 (5 - 90)
CAN 20 (7 - 60)
Median (Range)
These biopsies were therefore taken at an earlier stage than the clinical biopsies
studied and presented in the previous chapter and the majority were performed
during the first month following transplantation.
Only cortical tissue was available for study and only biopsies with at least three
glomeruli were included for study.
As demonstrated in Table 7.2 and Figure 7.1 there was a significant increase in MVC
in the biopsies from grafts which went on to develop CAN compared with stable
graft group.
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Table 7.2 - MVC in Protocol Biopsies from Patients with Stable Graft Function
vs. CAN










Mean MVC: Stable Grafts vs CAN: p=0.0238
There is a significantly higher MVC in grafts which go on to develop CAN than
those in which there is stable graft function.
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Figure 7.1 - Mean MVC in Protocol Biopsies from Patients with Stable Graft
Function vs. CAN
Protocol Bx: Stable Graft vs CAN
Mean and Standard Error
A B
Column
A - Stable Graft
B - Grafts which develop CAN
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Discussion
This study has demonstrated a highly significant expansion of microvasculature
during the first month after transplantation in allografts where CAN later develops.
It was not possible with the tissue available to assess for endothelial cell proliferation
in this population but it can be postulated that this must be present to explain the
higher MVCs described.
These data support our hypothesis that angiogenesis is stimulated early following
renal transplantation during the development ofCAN and this may provide a novel
therapeutic target in the treatment of these patients.
Further studies ofmediators of angiogenesis and graft macrophage infiltration in
these groups would be of great interest.
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Chapter 8: Discussion of changes in vascularity associated
with chronic allograft nephropathy
The present study addresses the changes in microvasculature seen in renal allografts
with histological changes ofCAN (Racusen 1997). The population of end-stage
CAN grafts studied had failed at varying times after transplantation resulting in
cessation of immunosuppressive therapy, return to renal replacement therapy and
graft nephrectomy.
A significant reduction in microvessel count (MVC) in end-stage CAN compared
with normal kidney was shown, demonstrating progressive loss ofmicrovasculature
with the development ofCAN. Previous studies using renal allograft biopsies have
shown a significant increase in microvessel density in chronic rejection (Ozdemir et
al 2001) and in the expression of the endothelial cell mitogen vascular endothelial
growth factor (VEGF) (Pilmore et al 1999). This suggests that earlier in the
progression ofCAN there may be attempts at expansion of the
microvasculature/angiogenesis in response to the hypoxia/insult of transplantation.
We tested this hypothesis further by performing MVCs on antecedent renal biopsy
specimens from our population of allografts but first sought to validate the use of this
technique with renal biopsy specimens.
Assessment of angiogenesis must involve methods which are reliable and
reproducible (Vermeulen et al 1996, Vermeulen et al 2002a). This study examined
variability in the assessment of angiogenesis in human kidney specimens by
comparing observer variation in reporting ofmicrovessel counts and by comparing
MVCs of paired specimens of normal kidney cross-section against core biopsy of the
same kidney.
A significant correlation between the two observers was demonstrated also at two
time points for one observer confirming this method to be reliable. Furthermore a
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significant correlation was demonstrated between core biopsies and cross sections of
the renal tissue studied, thus validating the use of this method.
The results of these studies were of vital importance and under-pinned the remaining
work undertaken which examined MVCs from renal biopsy specimens. Two sets of
biopsy samples were studied and have been referred to as clinical and protocol
biopsies.
The clinical biopsies were performed because of a clinical indication e.g. rising
serum creatinine or significant proteinuria. These biopsy samples were taken early in
the development ofCAN and paired with nephrectomy samples which demonstrated
end stage CAN. This allowed for comparison ofmicrovasculature at differing times
during CAN.
The clinical biopsies demonstrated a significantly higher MVC than the
corresponding nephrectomy with less distortion of normal microvasculature
demonstrated but showed a significant reduction in MVC compared to normal
kidney. This confirms both quantitavely and qualitatively that earlier in the
development ofCAN there was some (but not complete) preservation of normal
microvasculature. The present study does not demonstrate the same increase in
microvessel density as previous observers (Ozdemir et al 2002) however due to the
timing of specimen collection our data did not preclude an early rise in MVC
following transplantation. Thus protocol biopsies were used for study.
The protocol biopsies studied were taken during the first month following
transplantation and pre-dated the development ofCAN. It has been shown that the
Banff classification provides a reproducible method for histological assessment of
protocol renal allograft biopsies in stable grafts (Gough et al 2002). Such biopsies
also have value in detecting subclinical rejection and early CAN and may be used as
surrogate efficacy end points in evaluation of therapy in trials aimed to prevent CAN
(Gough et al 2002, Seron et al 2000). Despite these benefits, caution has been
advocated in their use in clinical decision making. Renal graft biopsy specimens
suffer from several limitations (sample size, timing of biopsy, reproducibility and
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specificity) and should only be used to complement other clinical criteria (Saad et al
1997, Ponticelli 13 Aug 2002). Furthermore, one study has reported the use of
protocol biopsies at 4 and 14 months to monitor the progression ofCAN as
inaccurate due to the relatively high proportion of misclassified biopsies (Seron et al
2002).
The protocol biopsies studied demonstrated a significantly higher MVC in grafts
which later developed CAN than those that did not or where stable graft function
continued. This highly significant result supports a hypothesis that angiogenesis is
stimulated early in the development ofCAN, the clinical significance of which is not
yet clear. To further assess the dynamic changes in microvasculature, studies were
performed to seek the presence of proliferating endothelial cells in CAN.
Dual immunostaining was performed to identify proliferating endothelial cells (ECs)
to assess for the presence ofEC repair and angiogenesis. Proliferating ECs were
almost absent in normal kidney. There was a significant increase in the number of
proliferating ECs in both the CAN nephrectomy specimens and the paired clinical
biopsies but no significant difference between these two groups. The presence of
proliferating ECs throughout the life of each graft suggests there is a constant
stimulus for tissue repair or that this stimulus has not been 'switched off. These
findings support the hypothesis outlined above but that over time, whilst there is
persisting evidence ofEC proliferation, progressive microvascular loss contributes to
the loss of the graft. Recent evidence has confirmed that there are two distinct phases
of injury as CAN evolves; an initial phase of early tubulointerstitial damage from
ischaemic injury and a later phase of chronic allograft nephropathy characterized by
microvascular and glomerular injury (Nankivell et al 2003). Furthermore,
glomerulosclerosis (GS) which is characteristic of CAN, has been demonstrated to be
a time-dependent response to glomerular injury from early ischaemia, immune-
mediated tubular loss and late CNI toxicity (Nankivell et al 2004a).
Immunostaining with antibody to CD31 does not exclusively stain the vascular
endothelium but can also stain lymphatics, thus the microvessel counts performed in
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this study may have demonstrated lymphatic as well as vascular changes. These
findings have since been investigated as part ofwork following on from this study by
immunostaining the same tissues with podoplanin antibody to lymphatic
endothelium. This has confirmed that in a subset of the grafts with CAN there is
evidence of lymphatic proliferation which is associated with ingress ofB
lymphocytes and VEGF-C expression (Adair et al 2006, unpublished). As B cells are
not known to release VEGF-C their effect may be mediated by macrophages which
this study has confirmed to be present in significantly higher numbers in end-stage
CAN. It is not clear why only just over half of the grafts studied demonstrated these
lymphatic changes whilst others did not.
In the other samples studied with podoplanin there was no evidence of significant
lyphangiogenesis confirming that the CD31 counts represent the vascular endothelial
staining in these sections.
Future work to establish means of diagnosing, monitoring, preventing and treating
CAN must be sought. Ultrasound elasticity imaging has been suggested as a useful
tool in measuring mechanical changes related to fibrosis within the transplant kidney
which may have efficacy in screening for early CAN (Weitzel et al 2004). The extent
of tubulointerstitial fibrosis (TIF) has been shown to correlate significantly with the
functional decline of grafts and a new method to quantify TIF has been developed
Sirius Red non-polarised strategy) which could be applied to longitudinal studies of
CAN (Diaz Encarnacion et al 2004).
As previously stated, a murine model ofCAN was not available for study, however
advances in the study ofCAN are being made in other animal models. More recently
it has been demonstrated that application of FTY720 in a rat model ameliorated CAN
even at advanced stages and that this effect was achieved by a reduction of graft
infiltrating lymphocytes (Wang et al 2004). Translation of these results to humans is
not always possible and the majority of current literature regarding treatment ofCAN
focuses on modulation of immunosuppressive regimens.
Discussion 167
The dominant theme in strategies to prevent CAN is to remove or replace long-term
calcineurin inhibitors (CNIs) such as cyclosporine or tacrolimus (Lo 2004).
Pathological changes ofCNI toxicity are virtually universal by 10 years and
exacerbated by CAN (Nankivell et al 2004b). The choice ofCNI may affect graft
outcome although this remains controversial. Whilst some authors report that
tacrolimus therapy projects a longer half life (Offermann 2004) with fewer chronic
lesions seen on biopsies (Toz et al 2004), these have not been randomised controlled
trials. One study has shown preliminary data which confirms that MMF/reduced dose
cyclosporine is superior to tacrolimus-for-cyclosporine switch and standard dose
cyclosporine for patients with CAN as demonstrated by analysis of reciprocal of
creatinine vs. time (ROCT) plots and GFR (Stoves et al 2004). One concern about
reduction or omission ofCNIs is that a higher incidence of acute rejection will
prevail and this is perhaps valid. It is interesting to note however that subclinical
acute rejection has not been shown to be associated with a poorer graft outcome
(Veronese et al 2004).
Optimisation of blood pressure, dyslipidaemia and the use of angiotensin 2 receptor
antagonists have also been advocated as potentially effective concurrent therapies in
patients with CAN (Aull 2004).
Expression of the chemokines MCP-1 and RANTES is significantly upregulated in
acute rejection compared with CAN and this correlated with momocyte/macrophage
infiltration (Ruster et al 2004). Since chemokines are not only involved in
inflammation but also tissue regeneration this could have impact on the development
ofCAN.
The protein-crosslinking enzyme, tissue transgluaminase (tTg) has been implicated
in renal fibrosis. tTg, and its crosslink product epsilon-(gamma-glutamyl) lysine,
correlated with the initiation and progression of scarring on sequential biopsies from
renal allograft recipients who experienced CAN (Johnson et al 2004). Elevated tTg
may therefore be an early predictor of the development ofCAN and tTg
manipulation to prevent fibrosis may offer an alternate therapeutic strategy.
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This thesis sought to examine a role for the therapeutic and prognostic implications
of changes in microvasculature during CAN. Angiogenesis has been widely studied
in cancer and inflammatory diseases and regulation of angiogenesis is governed by a
balance between pro- and anti-angiogenic mediators (Hanahan). Up-regulation of
VEGF has been shown in chronic renal allograft rejection (Pilmore 1999) and was
associated with the development of fibrosis. Recent work investigating the role of the
microvascular endothelium in progressive renal disease has demonstrated an early
proliferative response of the peritubular endothelium to injury (Kang 2001). This
proliferation was not sustained, with progressive capillary loss and interstitial
fibrosis. These changes were associated with alterations in the balance of angiogenic
mediators, specifically VEGF and the inhibitor of angiogenesis thrombospndin-1
(Kang 2001). In vitro study ofECs challenged by allogenic lymphmonocytes
demonstrated that smooth muscle cells co-cultured with ECs can be stimulated to
trans-differentiate from contractile to synthetic cells which further supports a role for
the ECs in the progression of the fibrosis seen in CAN (Amore 2001). It seems likely
that the changes in vascularity and EC proliferation we have described will depend
on the balance of angiogenic mediators within each graft and that VEGF may have
an important role. Defining changes in vascularity associated with CAN and the
mechanisms involved may allow for the development of novel diagnostic and
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Reagents for dewaxing of sections:
Xylene
Abs alcohol
Isopropanol MERCK Lot number: 102246L





Tris buffered saline (TBS):
TRIZMA base. SIGMA T - 1503 Lot number: 16H5738
Sodium chloride FISHERS/3120/53 Lot number: 9741598 227
0.9% solution prepared in distilled water, by adding 9g sodium chloride to 1 litre
distilled water.
Hydrochloric acid FISHER H/l 000/PB17
To make up TBS: 60.55g Trizma base was added to 1 litre distilled water and pH
optimized to 7.6 by the addition of concentrated hydrochloric acid.
0.05M TBS was used for staining; to achieve this concentration, lOOmls TBS was
added to 900ml 0.9% sodium chloride.
Phosphate buffered saline




Avidin biotin blocking kit VECTOR Lot number SP-2001
Serum free protein block DAKO X0909
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Reagents for antigen retrieval
Protease Type XXIV SIGMA P-8038 Lot number: 86H0561
Citric acid SIGMA C-7129 Lot number: 96H0355
Antigen unmasking solution VECTOR
Primary antibodies
Mouse anti-human CD31 monoclonal antibody. Clone JC/70A
DAKO M0823 Lot number: 016 (201)
Rat anti-mouse CD31 monoclonal antibody (MEC 13.3)
PHARMIGEN 0195ID Lot number: M022293
Rabbit anti-human VEGF polyclonal antibody.
SANTA CRUZ BIOTECHNOLOGY Code sc:507
Mouse anti-human MIB-1 monoclonal antibody
DAKO





Rabbit anti-mouse immunoglobulin (biotin)
Rabbit anti-rat immunoglobulin (APAAP)
Tertiary systems:
APAAP, mouse, monoclonal DAKO D0651 Lot number: 106 (101)
APAAP, rat, monoclonal DAKO D0488 Lot number: 046 (102)
ABC reagent VECTOR
Visualisation systems:




Xylene Substitute Mountant SHANDON code: 1900233
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Methods:
General Immunohistochemistry Protocol using ABC/DAB for CD68 and MIB-1
Antibodies
1. Dewax sections in 2 changes of xylene (5 mins each) and rehydrate through
graded alcohols: absolute alcohol 5 mins; 70% alcohol 5 mins; IMS 5 mins;
to distilled water.
2. Block endogenous peroxidase in 3% hydrogen peroxide for 10 mins (Sigma
code: H-1009: 30mls of this in 270mls distilled water).
3. Perform antigen retrieval as required (see footnote).
4. Wash in distilled water @ room temperature.
5. Transfer sections to sequenza (or equivalent) and wash through with TBS.
6. Using Vector blocking kit (code: SP-2001) apply 3 drops of Avidin per
section and leave for 10-15 mins. Wash briefly with TBS.
7. Apply3 drops of Biotin from same kit and leave for 10-15 mins. Wash with
TBS.
8. Apply 3 drops of Dako Protein Block (code: X0909) and leave for 15 mins.
9. Apply 100pi of primary antibody per section @ appropriate dilution. Leave
for 1 or 2 hours or overnight (depending on antibody). Wash in TBS.
10. Apply secondary antibody @ 1:300 at appropriate dilution. Leave for 30
mins. Wash in TBS.
11. Apply 3 drops of Vector ABC Vectastain reagent (code: PK-7100) per
section. Leave for 30 mins. Wash in TBS. Wash through with distilled water.
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12. Mark coverplates with waterproof pen (can be used 6 times each before
disposal).
13. Place sections on a staining rack over sink and cover with distilled water to
prevent them drying out.
14. Make up DAB using the Dako DAB kit (code: K3468). (Take suitable
precautions when using DAB). Wipe away water carefully around sections
and apply DAB. Leave on for 10 minutes. Dispose of surplus DAB carefully
in fume hood sink. Place sections in a staining rack and rinse well in tap
water.
15. Intensify in Copper Enhancement solution (6.66g cupric sulphate and 11.88g
sodium chloride dissolved in lOOOmls deionised water) for 5 mins and wash
again in tap water.
16. Counterstain with haematoxylin (1-2 min), differentiate in acid alcohol (dip
in a few times), blue in ammonia water (1 min). Check under microscope and
adjust counterstain as necessary.
17. Dehydrate through alcohols (IMS 5mins; 70% alcohol 5 mins; absolute
alcohol 5 mins), Clear through 2 changes of xylene (5 mins each) and mount
in DPX.
Footnote: Microwave Antigen Retrieval: Place sections in a plastic rack
inside a plastic Tupperware filled with Vector antigen retrieval solution and
microwave for 3 blasts of 5 minutes checking for evaporation between each
blast. Leave to cool for 20 minutes before transferring quickly to distilled
water, ensuring sections do not dry out.
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General Immunohistochemistry Protocol using APAAP/New Fuchsin for CD31
Antibodies
1. Dewax sections in 2 changes of xylene (5 mins each) and rehydrate through
graded alcohols: absolute alcohol 5 mins; 70% alcohol 5 mins; IMS 5 mins;
to distilled water.
2. Perform protease antigen retrieval (see footnote).
3. Transfer sections to sequenza or equivalent and wash through with TBS (pH
7.6).
4. Apply 3 drops of Dako Protein Block (serum free) (code: X0909) and leave
for 30 mins.
5. Apply primary CD31 antibody @ 1:20 dilution. Leave for 1 hour at room
temperature. Wash in TBS.
6. Apply secondary antibody (rabbit anti-mouse immunoglobulins) @ 1:50
dilution. Leave for 30 mins. Wash in TBS.
7. Apply APAAP reagent @ 1 TOO dilution. Leave for 30 mins. Wash in TBS.
8. Repeat steps 6 and 7 this time incubating each for only 10 minutes, to
enhance the signal. Mark coverplates and wash through with distilled water.
9. Place sections on a staining rack over sink and cover with distilled water to
prevent them drying out.
10. Make up New Fuchsin Substrate using kit (Dako code: K0698). Wipe round
sections and apply new fuchsin. Leave for 20 minutes.
11. Wash in distilled water.
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12. Counterstain with haematoxylin, differentiate in acid alcohol, blue in
ammonia water. Check under microscope and adjust counterstain as
necessary.
13. Dehydrate through alcohols (IMS 5mins; 70% alcohol 5 mins; absolute
alcohol 5 mins), clear through isopropanol (xylene dissolves new fuchsin)
and mount in Xylene Substitute Mountant (Shandon code: 1900233) or other
aqueous mountant.
Protease antigen retrieval - make up fresh for each use. Incubate sections in warm
distilled water heated to 37°C for 10 minutes. Make up protease (Sigma code: P-
8038) in the pre-warmed PBS (12.5mg/100ml PBS) and incubate slides in this for
exactly 20 minutes @ 37°C. Timing is crucial.
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Immunohistochemistry Protocol using ABC and APAAP for MIB-1/CD31 Dual
stain
1. (Pre-heat distilled water and PBS to 37°C if using protease for antigen
retrieval.)
2. Dewax sections in 2 changes of xylene (5 mins each) and rehydrate through
graded alcohols: absolute alcohol 5 mins; 70% alcohol 5 mins; IMS 5 mins;
to distilled water.
3. Block endogenous peroxidase in 3% hydrogen peroxide for 10 mins (Sigma
code: H-1009: 30mls of this in 270mls distilled water).
4. Perform microwave antigen retrieval.
5. Wash in distilled water @ room temperature.
6. Transfer sections to sequenza (or equivalent) and wash through with TBS.
7. Using Vector blocking kit (code: SP-2001) apply 3 drops of Avidin per
section and leave for 10-15 mins. Wash briefly with TBS.
8. Apply3 drops of Biotin from same kit and leave for 10-15 mins. Wash with
TBS.
9. Apply 3 drops ofDako Protein Block (code: X0909) and leave for 15 mins.
10. Apply 100pl of primary antibody per section @ appropriate dilution. Leave
for 1 or 2 hours or overnight (depending on antibody). Wash in TBS.
11. Apply secondary antibody @ 1:300 at appropriate dilution. Leave for 30
mins. Wash in TBS.
12. Apply 3 drops of Vector ABC Vectastain reagent (code: PK-7100) per
section. Leave for 30 mins. Wash in TBS. Wash through with distilled water.
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13. Mark coverplates with waterproof pen (can be used 6 times each before
disposal).
14. Place sections on a staining rack over sink and cover with distilled water to
prevent them drying out.
15. Make up DAB using the Dako DAB kit (code: K3468). (Take suitable
precautions when using DAB). Wipe away water carefully around sections
and apply DAB. Leave on for 10 minutes. Dispose of surplus DAB carefully
in fume hood sink. Place sections in a staining rack and rinse well in tap
water.
16. Intensify in Copper Enhancement solution (6.66g cupric sulphate and 11.88g
sodium chloride dissolved in lOOOmls deionised water) for 5 mins and wash
again in tap water (optional).
17. Transfer sections to sequenza or equivalent and wash through with TBS (pH
7.6).
18. Apply 3 drops of Dako Protein Block (serum free) (code: X0909) and leave
for 30 mins.
19. Apply primary antibody @ titrated dilution. Leave overnight. Wash in TBS.
20. Apply secondary antibody @ titrated dilution. Leave for 30 mins. Wash in
TBS.
21. Apply appropriate APAAP reagent @ titrated dilution. Leave for 30 mins.
Wash in TBS.
22. Repeat steps 20 and 21 this time incubating each for only 10 minutes, to
enhance the signal. Mark coverplates and wash through with distilled water.
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23. Place sections on a staining rack over sink and cover with distilled water to
prevent them drying out.
24. Make up New Fuchsin Substrate using kit (Dako code: K0698). Wipe round
sections and apply new fuchsin. Leave for 20 minutes.
25. Wash in distilled water.
26. Counterstain with haematoxylin, differentiate in acid alcohol, blue in
ammonia water. Check under microscope and adjust counterstain as
necessary.
27. Dehydrate through alcohols (IMS 5mins; 70% alcohol 5 mins; absolute
alcohol 5 mins), clear through isopropanol (xylene dissolves new fuchsin)




1. ParathyroidMVC and VEGF data
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Parathyroid MVC - Normal parathyroid
Pathology no. Count 1 Count 2 Count 3 Total MVC Tissue diagnosis
23029/94 4 4 2 10 normal
11524/96 2 2 2 6 normal
1509/96 II 2 1 1 4 normal
1530/96 I 4 3 3 10 normal
11509/96 II 3 6 2 11 normal
22101/98 II 6 5 8 19 normal
19452/98 II 8 4 3 15 normal
20923/96 III 4 2 6 12 normal
1634/97 II 3 5 4 12 normal
25101/98 I 3 3 5 11 normal
17799/98 I 9 4 4 17 normal
7857/93 III 11 18 14 43 normal
17623/97 II 3 4 4 11 normal
16558/96 II 5 5 3 13 normal
3455/99 IV 4 4 3 11 normal
16105/98 II 4 2 3 9 normal
4019/98 II 1 1 1 3 normal
10024/98 III 9 10 6 25 normal
10980/98 I 4 3 2 9 normal
23283/97 II 2 1 2 5 normal
8720/98 III 5 7 9 21 normal
10191/98 I 5 11 8 24 normal
17259/97 II 2 3 3 8 normal
17259/97 I 3 6 3 12 normal
23886/90 II 7 10 6 23 normal
3896/90 III 3 2 2 7 normal
8506/00 VI 5 3 4 11 normal
17565/90 III 3 4 3 10 normal
22481/98 III 3 4 3 10 normal
20923/96 IV 9 5 7 21 normal
23029/94 III 6 7 4 17 normal
20182/97 I 8 6 4 18 normal
4809/95 I 3 4 4 11 normal













Parathyroid MVC - Parathyroid adenoma
Pathology no. Count 1 Count 2 Count 3 Total MVC Tissue diagnosis
21705/92 9 10 23 42 adenoma
1530/96 23 9 10 42 adenoma
11509/96 17 17 10 44 adenoma
25806/94 17 11 5 33 adenoma
25381/91 19 11 4 34 adenoma
24157/91 13 11 7 31 adenoma
18293/93 10 8 7 25 adenoma
2519/92 10 8 14 32 adenoma
1634/97 10 11 7 28 adenoma
25300/98 21 11 18 50 adenoma
20236/97 12 9 10 31 adenoma
13580/90 9 8 12 29 adenoma
20764/90 5 6 3 14 adenoma
21374/90 3 3 4 10 adenoma
21693/90 10 11 6 27 adenoma
7045/90 5 3 4 12 adenoma
1840/91 12 14 15 41 adenoma
2608/91 6 5 7 18 adenoma
283/91 25 9 7 41 adenoma
2395/91 11 18 10 39 adenoma
12274/91 18 20 9 47 adenoma
20282/91 13 6 6 25 adenoma
19361/91 8 9 9 26 adenoma
19028/91 10 7 11 28 adenoma
17589/90 6 3 4 13 adenoma
25101/97 7 10 9 26 adenoma
22101/98 10 11 8 29 adenoma
19452/98 10 9 8 27 adenoma
16558/96 14 12 10 36 adenoma
1331/95 8 10 7 25 adenoma
20303/95 13 25 16 54 adenoma
1509/96 9 24 14 47 adenoma
23029/94 I 14 11 10 35 adenoma
7857/93 11 8 9 28 adenoma
3956/98 8 11 16 35 adenoma
25632/96 12 9 8 29 adenoma
656/98 21 17 14 52 adenoma
9186/98 10 14 10 34 adenoma
17259/97 4 5 3 12 adenoma
23283/97 7 6 7 20 adenoma
16105/98 9 10 13 32 adenoma
4019/98 11 11 9 31 adenoma
10980/98 II 9 14 10 33 adenoma
9826/90 12 7 10 29 adenoma
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Parathyroid MVC - Parathyroid hyperplasia
Pathology no. Count 1 Count 2 Count 3 Total MVC Tissue diagnosis
13449/96 5 10 12 27 hyperplasia
13481/96 8 6 5 19 hyperplasia
7636/97 10 8 10 28 hyperplasia
12252/96 8 8 8 24 hyperplasia
12887/96 17 7 10 39 hyperplasia
8018/96 8 7 7 23 hyperplasia
18043/95 12 11 5 28 hyperplasia
10867/98 13 8 8 29 hyperplasia
6895/92 4 2 2 8 hyperplasia
25902/95 6 6 4 16 hyperplasia
8716/97 6 11 8 25 hyperplasia
12247/96 3 5 4 12 hyperplasia
4527/97 4 4 4 12 hyperplasia
14883/99 7 14 11 32 hyperplasia
4527/97 9 7 6 22 hyperplasia
3455/99 10 7 8 25 hyperplasia
8497/00 9 6 8 23 hyperplasia
14883/99 9 14 10 33 hyperplasia
14737/99 19 12 8 39 hyperplasia
9298/98 9 10 11 30 hyperplasia
7190/98 19 15 10 44 hyperplasia
26254/99 9 9 11 29 hyperplasia
14883/99 7 10 7 24 hyperplasia
1307/97 10 6 7 23 hyperplasia
8174/98 8 9 10 27 hyperplasia
14883/99 I 4 3 5 12 hyperplasia
4651/97 5 3 4 12 hyperplasia
3560/97 7 3 4 14 hyperplasia
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24157/91 II 2 1 Normal
2519/92 II 2 1 Normal
23581/91 II 2 1 Normal
1509/96 II 3 3 Normal
20303/95 II 1 1 Normal
2815/92 II 2 2 Normal
21705/92 II 1 3 Normal
7857/93 III 1 1 Normal
18293/93 II 2 1 Normal
23029/94 II 2 2 Normal
13311/95 II 2 2 Normal
13449/96 I 1 1 Normal
25806/94 II 2 1 Normal
20684/91 III 1 1 Normal
20282/91 III 1 1 Normal
16558/96 II 1 1 Normal
20923/96 I 2 1 Normal
19028/91 II 3 1 Normal
17259/97 III 3 1 Normal
2608/91 II 1 1 Normal
19361/91 II 1 1 Normal
17623/97 II 2 1 Normal
7045/90 II 1 1 Normal
11509/96 II 2 1 Normal
23886/90 III 1 1 Normal
17565/90 I 1 1 Normal
11524/96 II 1 1 Normal
20923/96 III 3 3 Normal
1634/97 II 2 1 Normal
16105/98 II 1 1 Normal
13580/90 II 3 1 Normal
17799/98 II 2 3 Normal
17799/98 II 1 1 Normal
21693/90 II 2 3 Normal
19452/98 II 2 2 Normal
9826/90 III 1 1 Normal
22101/98 II 2 3 Normal
283/91 I 3 2 Normal
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22101/98 I 3 1 Adenoma
283/91 II 1 3 Adenoma
9826/90 II 2 1 Adenoma
19452/98 I 1 1 Adenoma
21693/90 I 1 1 Adenoma
17799/98 I 3 1 Adenoma
13580/90 I 3 1 Adenoma
11524/96 I 1 1 Adenoma
23886/90 I 2 2 Adenoma
17623/97 I 1 1 Adenoma
17259/97 I 1 2 Adenoma
1634/97 II 1 3 Adenoma
17589/90 I 0 0 Adenoma
20764/90 I 1 1 Adenoma
21374/90 I 1 1 Adenoma
7045/90 I 1 1 Adenoma
16558/96 I 1 1 Adenoma
12274/91 I 1 1 Adenoma
2608/91 I 1 1 Adenoma
11509/96 I 1 Adenoma
7857/93 IV 1 1 Adenoma
13311/95 I 2 1 Adenoma
2395/91 I 3 1 Adenoma
20282/91 II 2 1 Adenoma
20684/91 II 0 Adenoma
24157/91 I 2 1 Adenoma
18840/91 II 0 Adenoma
18293/93 I 1 1 Adenoma
19361/91 II 0 Adenoma
19028/91 I 1 1 Adenoma
1509/96 I 1 1 Adenoma
2519/92 I 0 Adenoma
21705/92 I 1 1 Adenoma
23029/94 I 2 Adenoma
23581/91 I 1 1 Adenoma
20303/95 I 2 1 Adenoma
25806/94 I 3 1 Adenoma
2815/92 III 1 1 Adenoma
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8018/96 3 1 Hyperplasia
12247/96 I 3 1 Hyperplasia
12252/96 II 1 1 Hyperplasia
12887/96 I 1 1 Hyperplasia
4527/97 I 1 1 Hyperplasia
7636/97 III 1 1 Hyperplasia
8716/97 I 1 1 Hyperplasia
23571/90 I 1 Hyperplasia
13449/96 III 1 Hyperplasia
25902/95 I 1 1 Hyperplasia
3560/97 III 1 Hyperplasia
6895/92 I 1 1 Hyperplasia
18043/95 I 1 1 Hyperplasia
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2. Validation of microvessel counts in renal biopsy specimens
Appendices
Normal kidney MVC comparing cross section (XS) and biopsy (Bx) from same
kidney - Cortex
Specimen XS glomeruli XS count Bx glomeruli Bx count
K1 4 25 4 25
K2 3 22 2 19
K3 6 20 5 20
K4 3 30 3 28
K5 5 27 3 27
K6 3 31 n/a n/a
K7 4 29 4 28
K8 3 20 n/a n/a
K9 4 32 3 21
K10 4 23 3 22
K11 5 21 4 20
K12 3 17 4 22
K13 4 20 3 20
K14 4 14 n/a n/a
K15 4 25 n/a n/a
K16 3 22 3 21
K17 3 20 3 20
K18 4 22 6 22
K19 7 24 3 20
K20 n/a n/a n/a n/a
K21 3 21 n/a n/a
K22 5 17 n/a n/a
K23 4 23 3 22
K24 4 18 3 18
K25 3 12 3 11
K26 3 21 4 16
K27 5 20 2 20
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Normal kidney MVC comparing cross section (XS) and biopsy (Bx) from same
kidney - Medulla





























3. Comparing microvessel counts in renal tumours and normal
kidney
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Tumour MVC comparing cross section (XS) and biopsy (Bx) from same kidney































K2 22 30 n/a
K3 20 18 37
K4 30 23 n/a
K5 27 20 30
K6 31 17 30
K7 29 22 23
K8 20 21 n/a
K9 32 22 22
K10 23 18 21
K11 21 20 20
K12 17 17 28
K13 20 13 24
K14 14 20 29
K15 25 27 35
K16 22 25 33
K17 20 23 26
K18 22 21 23
K19 24 n/a n/a
K20 n/a n/a 40
K21 21 n/a 20
K22 17 n/a 21
K23 23 16 n/a
K24 18 16 23
K25 12 n/a 28
K26 21 n/a 22
K27 20 22 29
Appendices 242
Normal vs. Tumour MVC from the same kidney - biopsy
Specimen
Tumour
BX Normal Cortex Bx
Normal Medulla
Bx
K2 n/a 19 27
K3 26 20 n/a
K4 n/a 28 22
K5 22 27 n/a
K6 n/a n/a 18
K7 22 28 22
K8 n/a n/a 22
K9 20 21 25
K10 23 22 16
K11 22 20 20
K12 31 22 n/a
K13 28 20 19
K14 30 n/a 20
K15 29 n/a 26
K16 38 21 24
K17 29 20 n/a
K18 24 22 20
K19 n/a 20 n/a
K20 37 n/a n/a
K21 24 n/a n/a
K22 15 n/a n/a
K23 n/a 22 16
K24 27 18 15
K25 27 11 n/a
K26 20 16 n/a
K27 27 20 20
Median MVC for both Cross Section and Biopsies from Normal Kidney and
Tumour
Normal Cortex Normal Medulla Tumour
Cross Sections 21 20.5 26
Biopsies 20 20 26.5
Student t test p<0.05
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4. Reproducibility of microvessel counts in human kidney specimens
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Intra-observer variation. Counts for DM - cortex
Specimen DM count 1 DM count 2
K1 XS 24 27
K2XS 22 20
K3 XS 20 21
K4XS 30 26
K5 XS 27 27
K6XS 31 33
K7 XS 29 26
K8 XS 20 21
K9 XS 31 28
K10XS 22 22









K21 XS 23 25
K22 XS 17 17
K23 XS 21 19
K24 XS 18 12
K25 XS 12 12
K26 XS 20 22
K27 XS 20 18
K1 Bx 24 21
K2 Bx 18 23
K3 Bx 20 19
K4 Bx 26 27
K5 Bx 27 25
K7 Bx 28 27
K9 Bx 21 20
K10 Bx 22 22
K11 Bx 20 21
K12 Bx 22 20
K13 Bx 19 20
K15 Bx 21 21
K16 Bx 21 19
K17 Bx 20 19
K18 Bx 21 22
K19 Bx 20 22
K23 Bx 22 21
K24 Bx 19 14
K25 Bx 11 12
K26 Bx 16 15
K27 Bx 19 15
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K1 XS 28 27
K2XS 30 25
K3 XS 18 20
K4XS 23 23
K5 XS 20 18
K6XS 16 20
K7 XS 22 21
K8 XS 20 19
K9 XS 20 21
K10XS 18 21








K23 XS 15 16
K24 XS 15 16
K27 XS 22 21
K1 Bx 28 27
K4 Bx 21 24
K6 Bx 19 21
K7 Bx 23 21
K8 Bx 21 21
K9 Bx 24 20
K10 Bx 15 16
K11 Bx 20 20
K13 Bx 18 18
K14 Bx 20 21
K15 Bx 26 24
K16 Bx 23 24
K18 Bx 20 21
K23 Bx 14 12
K24 Bx 15 14
K27 Bx 20 18
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Inter-observer Variation. DM and LM counts -Medulla























4. Changes in vascularity associated with chronic allograft
nephropathy
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UB 018110R/93 14 8977 21 K1 25
UB
011928M/00 14 9231 n/a K2 22
UB 020768A/95 18 9493 22 K3 20
UB 018837C/94 12 9644 23 K4 30
UB 017742C/02 13 10333 23 K5 27
UB
003798M/99 16 11073 27 K6 31
UB 019010F/00 18 11406 27 K7 29
UB 005718S/02 16 11940 25 K8 20
UB 016885J/02 n/a 11964 22 K9 32
UB 006779/90 17 12242i 29 K10 23
UB 011293B/01 13 12242j 20 K11 21
UB 017246P/00 18 12851 20 K12 17
UB 026006T/02 22 13394 22 K13 20
UB 023656F/98 13 462 22 K14 14
UB 017275K/96 17 897 26 K15 25
UB 023572K/94 15 899 22 K16 22
UB 018005S/99 11 1426 17 K17 20
UB 021907/95 16 2005 21 K18 22
UB 020561H/91 14 2226 30 K19 24
UB 018961G/97 12 2526 20 K20 n/a
UB 014924S/00 14 4152 22 K21 21
UB 020972L/90 13 4381 22 K22 17
UB 024483B/00 15 4502 26 K23 23
UB 001909C/98 14 5196 24 K24 18
UB 012398L/98 12 5192 21 K25 12
UB 002921C/96 14 6552 25 K26 21
UB 012066A/01 15 7439 19 K27 20
UB 003081/97 12 7812 19
UB 006358/97 18 7945 20
UB 008353/98 21 8880 21
UB 019767/99 12 9325 28
UB 005247/00 16 9943 21
UB 023079/01 15 10083 23
UB 023957/01 15 10521 21
UB 025179/01 18 10879 20
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UB 018110R/93 n/a 8977 19 K1 29
UB
011928M/00 14 9231 n/a K2 30
UB 020768A/95 14 9493 20 K3 18
UB 018837C/94 n/a 9644 n/a K4 23
UB 017742C/02 15 10333 25 K5 20
UB
003798M/99 18 11073 24 K6 17
UB 019010F/00 15 11406 19 K7 22
UB 005718S/02 17 11940 23 K8 21
UB 016885J/02 16 11964 n/a K9 22
UB 006779/90 15 12242i n/a K10 18
UB 011293B/01 14 12242j n/a K11 20
UB 017246P/00 14 12851 n/a K12 17
UB 026006T/02 23 13394 25 K13 13
UB 023656F/98 14 462 22 K14 20
UB 017275K/96 14 897 25 K15 27
UB 023572K/94 11 899 21 K16 25
UB 018005S/99 22 1426 n/a K17 23
UB 021907/95 13 2005 n/a K18 21
UB 020561H/91 15 2226 29 K19 n/a
UB 018961G/97 14 2526 18 K20 n/a
UB 014924S/00 16 4152 24 K21 n/a
UB 020972L/90 n/a 4381 21 K22 n/a
UB 024483B/00 17 4502 25 K23 16
UB 001909C/98 18 5196 26 K24 16
UB 012398L/98 18 5192 n/a K25 n/a
UB 002921C/96 19 6552 n/a K26 n/a
UB 012066A/01 12 7439 18 K27 22
UB 003081/97 11 7812 18
UB 006358/97 13 7945 19
UB 008353/98 17 8880 21
UB 019767/99 14 9325 26
UB 005247/00 12 9943 17
UB 023079/01 16 10083 24
UB 023957/01 13 10521 22
UB 025179/01 11 10879 17
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No. of Proliferating Endothelial Cells (ECs) and Proliferation Index - Normal
Kidney
Specimen No. proliferating ECs
Total no. proliferating
cells Proliferation Index
K1 0 13 0
K2 0 11 0
K3 0 6 0
K4 1 18 0.055555556
K5 1 9 0.111111111
K6 0 16 0
K7 0 6 0
K8 0 7 0
K9 0 14 0
K10 0 13 0
K11 1 21 0.047619048
K12 2 17 0.117647059
K13 1 11 0.090909091
K14 0 12 0
K15 0 9 0
K16 1 15 0.066666667
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No. of Proliferating Endothelial Cells (ECs) and Proliferation Index - CAN
Nephrectomy
Specimen
number No. proliferating ECs
Total no. proliferating
cells Proliferation Index
UB 011928M/00 3 25 0.12
UB 020768A/95 5 22 0.227272727
UB 018837C/94 4 19 0.210526316
UB 017742C/02 3 20 0.15
UB 003798M/99 4 26 0.153846154
UB 019010F/00 8 26 0.307692308
UB 005718S/02 6 30 0.2
UB 006779/90 1 15 0.066666667
UB 011293B/01 4 29 0.137931034
UB 017246P/00 9 33 0.272727273
UB 023572K/94 3 22 0.136363636
UB 018005S/99 2 18 0.111111111
UB 021907/95 5 23 0.217391304
UB 014924S/00 5 27 0.185185185
UB 001909C/98 3 21 0.142857143
UB 012066A/01 15 51 0.294117647
UB 005247/00 6 24 0.25
UB 023957/01 5 26 0.192307692
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Glomerular macrophage infiltration - Normal Kidney
Normal Specimen No. glomeruli CD68 count Index
13394 20 70 3.5
11073 20 47 2.35
11406 20 37 1.85
11837 20 25 1.25
10333 20 78 3.9
9881 h 20 34 1.7
9881q 20 43 2.15
9644 20 35 1.75
9493 20 27 1.35
9231 20 57 2.85
8977 20 40 2
7501 20 31 1.55
11940 20 70 3.5
11964 20 29 1.45
11242i 20 62 3.1
11242j 20 54 2.7
12851 20 50 2.5
462 20 38 1.9
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Glomerular macrophage infiltration - CAN Nephrectomy
CAN
Specimen No. glomeruli CD68 count Index
90/20972 20 40 2
91/20561 n/a n/a n/a
93/18110 20 51 2.55
94/18837 10 19 1.9
94/23572 20 31 1.55
95/20768 13 38 2.923076923
96/2921 n/a n/a n/a
96/17275 20 40 2
97/3081 20 77 3.85
97/6358 20 43 2.15
98/8353 10 31 3.1
98/12398 20 65 3.25
98/23656 n/a n/a n/a
99/3798 20 41 2.05
99/18005 20 46 2.3
99/19767 20 53 2.65
00/5247 20 55 2.75
00/11928 20 35 1.75
00/14924 20 44 2.2
97/18961 14 51 3.642857143
98/1909 20 50 2.5
00/17246 20 73 3.65
00/19010 20 81 4.05
01/11293 20 59 2.95
01/12066 20 62 3.1
01/23079 20 61 3.05
01/23937 20 64 3.2
01/25179 20 77 3.85
002/5718 20 79 3.95
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5. Microvessel counts from Renal Allograft Biopsies
Appendices




biopsy Specimen Normal kidney Specimen
Normal kidney
cont.
UB 020921V/91 15 8977 21 K1 25
UB 012868T/91 18 9231 n/a K2 22
UB 015453R/98 n/a 9493 22 K3 20
UB 004420Q/99 20 9644 23 K4 30
UB 013491F/99 15 10333 23 K5 27
UB 019454/91 17 11073 27 K6 31
UB 019262V/90 20 11406 27 K7 29
UB 003815V/92 n/a 11940 25 K8 20
UB 017016/00 21 11964 22 K9 32
UB 027355Y/98 20 12242i 29 K10 23
UB 0191337795 18 12242j 20 K11 21
UB 006498/99 20 12851 20 K12 17
UB 026369/98 18 13394 22 K13 20
UB 001832/90 17 462 22 K14 14
UB 114829X/01 23 897 26 K15 25
UB 020812/97 22 899 22 K16 22
UB 008225/01 18 1426 17 K17 20
UB 007465/00 18 2005 21 K18 22
UB 021053/98 19 2226 30 K19 24
UB 09383/94 14 2526 20 K20 n/a
UB 010405/91 18 4152 22 K21 21
UB 016595/95 n/a 4381 22 K22 17
UB 014897/94 n/a 4502 26 K23 23
UB 011967/94 23 5196 24 K24 18
UB 027357D/96 n/a 5192 21 K25 12
UB 014750K/94 21 6552 25 K26 21
UB 011516J/98 n/a 7439 19 K27 20
UB 017819W/95 17 7812 19
UB 007215Y/01 13 7945 20
UB 020654F/00 20 8880 21
UB 002734/95 18 9325 28














UB 020921V/91 12 8977 19 K1 29
UB 012868T/91 14 9231 n/a K2 30
UB 015453R/98 n/a 9493 20 K3 18
UB 004420Q/99 25 9644 n/a K4 23
UB 013491F/99 21 10333 25 K5 20
UB 019454/91 n/a 11073 24 K6 17
UB 019262V/90 n/a 11406 19 K7 22
UB 003815V/92 n/a 11940 23 K8 21
UB 017016/00 n/a 11964 n/a K9 22
UB 027355Y/98 13 12242i n/a K10 18
UB 019133T/95 n/a 12242j n/a K11 20
UB 006498/99 n/a 12851 n/a K12 17
UB 026369/98 n/a 13394 25 K13 13
UB 001832/90 n/a 462 22 K14 20
UB 114829X/01 n/a 897 25 K15 27
UB 020812/97 n/a 899 21 K16 25
UB 008225/01 20 1426 n/a K17 23
UB 007465/00 15 2005 n/a K18 21
UB 021053/98 14 2226 29 K19 n/a
UB 09383/94 n/a 2526 18 K20 n/a
UB 010405/91 18 4152 24 K21 n/a
UB 016595/95 17 4381 21 K22 n/a
UB 014897/94 16 4502 25 K23 16
UB 011967/94 22 5196 26 K24 16
UB 027357D/96 12 5192 n/a K25 n/a
UB 014750K/94 n/a 6552 n/a K26 n/a
UB 011516J/98 18 7439 18 K27 22
UB 017819W/95 13 7812 18
UB 007215Y/01 n/a 7945 19
UB 020654F/00 n/a 8880 21
UB 002734/95 n/a 9325 26





Cortical MVC comparing Clinical Biopsies according to Time after
Transplantation (months)
Timing after Tx <12 >12 <36 >36 <12 >12
MVC 17 15 17 17 15
21 18 14 21 18
20 20 13 20 20
18 15 23 18 15
18 20 18 20
18 19 18 19






MVC comparing All CAN Nephrectomy with All Clinical Biopsy - Cortex
Patient initial Specimen number Nephrectomy Patient initial Specimen number Biopsy
RS UB 018110R/93 14 RS UB 020921V/91 15
H R UB 011928M/00 14 UB 012868T/91 18
M C UB 020768A/95 18 H R UB 015453R/98 n/a
AD UB 018837C/94 12 UB 004420Q/99 20
J G UB 017742C/02 13 UB 013491F/99 15
AK UB 003798M/99 16 M C UB 019454/91 17
G M UB 019010F/00 18 A D UB 019262V/90 20
AM UB 005718S/02 16 UB 003815V/92 n/a
M S UB 016885J/02 n/a J G UB 017016/00 21
M S UB 006779/90 17 AK UB 027355Y/98 20
M B UB 011293B/01 13 G M UB 019133T/95 18
B G UB 017246P/00 18 UB 006498/99 20
AC UB 026006T/02 22 M S UB 026369/98 18
G G UB 023656F/98 13 M S UB 001832/90 17
F L UB 017275K/96 17 TL UB 114829X/01 23
R B UB 023572K/94 15 UB 020812/97 22
M H UB 018005S/99 11 M B UB 008225/01 18
M H UB 021907/95 16 BG UB 007465/00 18
A J UB 020561H/91 14 UB 021053/98 19
A J UB 018961G/97 12 R B UB 09383/94 14
D K UB 014924S/00 14 UB 010405/91 18
N M UB 020972L/90 13 AD UB 016595/95 n/a
D M UB 024483B/00 15 UB 014897/94 n/a
J O UB 001909C/98 14 M H UB 011967/94 23
R R UB 012398L/98 12 A J UB 027357D/96 n/a
AS UB 002921C/96 14 J O UB 014750K/94 21
AD UB 012066A/01 15 R R UB 011516J/98 n/a
H W UB 003081/97 12 AS UB 017819W/95 17
AJ D UB 006358/97 18 AD UB 007215Y/01 13
J D UB 008353/98 21 UB 020654F/00 20
AC UB 019767/99 12 H W UB 002734/95 18
G D UB 005247/00 16 E M UB 026073/94 n/a
E M UB 023079/01 15
TL UB 023957/01 15
WM UB 025179/01 18
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MVC comparing All CAN Nephrectomy with All Clinical Biopsy - Medulla
Patient initial
Specimen
number Nephrectomy Patient initial
Specimen
number Biopsy
R S UB 018110R/93 n/a RS UB 020921V/91 12
H R
UB
011928M/00 14 UB 012868T/91 14
M C UB 020768A/95 14 H R UB 015453R/98 n/a
A D UB 018837C/94 n/a UB 004420Q/99 25
J G UB 017742C/02 15 UB 013491F/99 21
A K
UB
003798M/99 18 M C UB 019454/91 n/a
G M UB 019010F/00 15 AD UB 019262V/90 n/a
AM UB 005718S/02 17 UB 003815V/92 n/a
M S UB 016885J/02 16 J G UB 017016/00 n/a
M S UB 006779/90 15 AK UB 027355Y/98 13
M B UB 011293B/01 14 G M UB 019133T/95 n/a
B G UB 017246P/00 14 UB 006498/99 n/a
AC UB 026006T/02 23 M S UB 026369/98 n/a
G G UB 023656F/98 14 M S UB 001832/90 n/a
F L UB 017275K/96 14 TL UB 114829X/01 n/a
R B UB 023572K/94 11 UB 020812/97 n/a
M H UB 018005S/99 22 M B UB 008225/01 20
M H UB 021907/95 13 BG UB 007465/00 15
A J UB 020561H/91 15 UB 021053/98 14
A J UB 018961G/97 14 R B UB 09383/94 n/a
D K UB 014924S/00 16 UB 010405/91 18
N M UB 020972L/90 n/a AD UB 016595/95 17
D M UB 024483B/00 17 UB 014897/94 16
J O' UB 001909C/98 18 M H UB 011967/94 22
R R UB 012398L/98 18 A J UB 027357D/96 12
AS UB 002921C/96 19 JO UB 014750K/94 n/a
AD UB 012066A/01 12 R R UB 011516J/98 18
H W UB 003081/97 11 AS UB 017819W/95 13
AJ D UB 006358/97 13 AD UB 007215Y/01 n/a
J D UB 008353/98 17 UB 020654F/00 n/a
AC UB 019767/99 14 H W UB 002734/95 n/a
G D UB 005247/00 12 E M UB 026073/94 16
E M UB 023079/01 16
TL UB 023957/01 13
WM UB 025179/01 11
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MVC comparing specific CAN Nephrectomy and Clinical Biopsy pairs - Cortex



















MVC comparing specific CAN Nephrectomy and Clinical Biopsy pairs -
Medulla








































UB 019010F/00 8 UB 019133T/95 5
UB 005718S/02 6 UB 006498/99 5
UB 006779/90 1 UB 001832/90 2
UB 011293B/01 4 UB 020812/97 3
UB 017246P/00 9 UB 008225/01 4
UB 023572K/94 3 UB 007465/00 7
UB 018005S/99 2 UB 021053/98 6
UB 021907/95 5 UB 010405/91 3








Glomerular macrophage infiltration - Early Clinical Biopsy
Specimen Earliest Bx Bx
number glomeruli count Bx Index
UB 021053/98 7 9 1.285714
UB 010405/91 13 12 0.923077
UB 011683B/93 1 1 1
UB 020654F/00 15 33 2.2
UB 014897/94 9 16 1.777778
UB 015453R/98 7 5 0.714286
UB 019454/91 4 11 2.75
UB 027355Y/98 8 12 1.5
UB 001832/90 3 8 2.666667
UB 017016/00 5 13 2.6
UB 019133T/95 4 7 1.75
UB 008225/01 5 12 2.4
UB 014750K/94 10 22 2.2
UB 002734/95 11 13 1.181818
UB 020812/97 10 14 1.4
Glomerular macrophage infiltration - Late Biopsy
Specimen
number Later Bx glomeruli
Bx
Count Bx index
UB 021053/98 7 16 2.285714
UB 09383/94 10 18 1.8
UB 007215Y/01 7 13 1.857143
UB 013491F/99 2 2 1
UB 006498/99 3 7 2.333333
UB 114829X/01 10 16 1.6
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MVC from Protocol Biopsies - All counts





527 31/07/1985 20 Y 14 22
531 02/09/1985 7 N 12 22
533 03/03/1986 155 Y 2 15
558 17/01/1986 10 Y 10 20
558 29/01/1986 21 Y 7 21
605 28/11/1986 90 N n/a n/a
619 20/02/1987 90 N 4 16
721 26/09/1988 210 N 4 15
755 05/10/1988 24 N 3 20
755 16/09/1988 5 N 3 16
755 21/09/1988 10 N 1 14
757 28/09/1988 11 N 6 23
758 18/10/1988 30 N n/a n/a
758 23/09/1988 5 N 3 15
758 04/10/1988 16 N n/a n/a
759 07/10/1988 16 N n/a n/a
759 16/10/1988 25 N 1 5
764 21/10/1988 13 Y n/a n/a
764 24/10/1988 16 Y 1 13
766 27/11/1988 32 Y n/a n/a
766 02/11/1988 7 Y 7 24
766 09/11/1988 14 Y 4 22
840 22/08/1989 7 years Y n/a n/a
894 10/04/1990 60 Y 3 19
898 19/03/1990 7 N 2 18
898 01/04/1990 20 N 4 17
898 16/04/1990 35 N n/a n/a
903 04/05/1990 28 N 3 14
904 04/05/1990 22 N 3 18
905 20/04/1990 6 N 3 20
905 31/05/1990 44 N 4 17
906 01/05/1990 16 Y n/a n/a
906 04/05/1990 19 Y n/a n/a
911 05/06/1990 27 N n/a n/a
915 25/05/1990 5 N 6 25
915 10/06/1990 21 N 3 18
918 04/07/1990 9 N 3 14
921 12/06/1990 6 Y n/a n/a
944 10/09/1996 6 years N 2 18
965 31/01/1991 34 Y 7 25
1067 05/04/1992 4 years N n/a n/a
1092 24/06/1992 7 N n/a n/a
1351 22/08/1996 300 GN 3 14
1362 26/02/1996 29 N 1 8
1383 18/06/1996 50 Y 6 24
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1391 05/07/1996 28 N 5 16
1395 01/07/1996 14 N n/a n/a
1404 30/08/1996 26 N 5 17
1404 29/08/1996 18 N 6 19
1406 28/08/1996 10 N 5 19
1406 11/09/1996 28 N 7 21
1408 20/09/1996 30 N 1 14
1413 20/09/1996 10 N 10 23
1454 29/11/1997 8 month N 3 15
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MVC from protocol biopsies - Stable graft function (<6 month, >3 glomeruli)





531 02/09/1985 7 N 12 22
619 20/02/1987 90 N 4 16
755 05/10/1988 24 N 3 20
755 16/09/1988 5 N 3 16
757 28/09/1988 11 N 6 23
758 23/09/1988 5 N 3 15
898 01/04/1990 20 N 4 17
903 04/05/1990 28 N 3 14
904 04/05/1990 22 N 3 18
905 20/04/1990 6 N 3 20
905 31/05/1990 44 N 4 17
915 25/05/1990 5 N 6 25
915 10/06/1990 21 N 3 18
918 04/07/1990 9 N 3 14
1391 05/07/1996 28 N 5 16
1404 30/08/1996 26 N 5 17
1404 29/08/1996 18 N 6 19
1406 28/08/1996 10 N 5 19
1406 11/09/1996 28 N 7 21
1413 20/09/1996 10 N 10 23
MVC from protocol biopsies - CAN (<6 month, >3 glomeruli)
527 31/07/1985 20 Y 14 22
558 17/01/1986 10 Y 10 20
558 29/01/1986 21 Y 7 21
766 02/11/1988 7 Y 7 24
766 09/11/1988 14 Y 4 22
894 10/04/1990 60 Y 3 19
965 31/01/1991 34 Y 7 25
1383 18/06/1996 50 Y 6 24
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